



G6P-capturing molecules in the periplasm of *Escherichia coli* accelerate the shikimate pathway

Fujiwara, Ryosuke ; Nakano, Mariko ; Hirata, Yuuki ; Otomo, Chisako ; Nonaka, Daisuke ; Kawada, Sakiya ; Nakazawa, Hikaru ; Umetsu, Mitsuo ;...

(Citation)

Metabolic Engineering, 72:68-81

(Issue Date)

2022-07

(Resource Type)

journal article

(Version)

Accepted Manuscript

(Rights)

© 2022 International Metabolic Engineering Society. Published by Elsevier Inc.
This manuscript version is made available under the CC-BY-NC-ND 4.0 license
<http://creativecommons.org/licenses/by-nc-nd/4.0/>

(URL)

<https://hdl.handle.net/20.500.14094/90009278>



Highlights

- Periplasmic expression of β -glucosidase (BGL) increases L-Phe production in *E. coli*
- Two key factors involved in this phenomenon, G6P and EIIC^{Glc} domain, were defined
- Cytoplasmic G6P is secreted into the periplasm via EIIC^{Glc} domain and captured by BGL
- Periplasmic expression of other G6P-capturing proteins also increase L-Phe production
- This technique can be applied to produce other shikimate pathway derivatives

Author Contributions

Ryosuke Fujiwara: Conceptualization, Methodology, Formal Analysis, Investigation, Writing—Original Draft.

Mariko Nakano: Investigation.

Yuuki Hirata: Investigation.

Chisako Otomo: Investigation.

Daisuke Nonaka: Investigation.

Sakiya Kawada: Investigation.

Hikaru Nakazawa: Investigation.

Mitsuo Umetsu: Investigation.

Tomokazu Shirai: Methodology.

Shuhei Noda: Conceptualization, Methodology, Formal Analysis, Investigation, Writing—Review & Editing.

Tsutomu Tanaka: Conceptualization, Methodology, Formal Analysis, Investigation, Writing—Review & Editing.

Akihiko Kondo: Supervision

G6P-capturing molecules in the periplasm of *Escherichia coli* accelerate the shikimate pathway

Ryosuke Fujiwara^{a,†}, Mariko Nakano^a, Yuuki Hirata^a, Chisako Otomo^a, Daisuke Nonaka^a, Sakiya Kawada^b, Hikaru Nakazawa^b, Mitsuo Umetsu^b, Tomokazu Shirai^c, Shuhei Noda^{c,*}, Tsutomu Tanaka^{a,*}, Akihiko Kondo^{c,d}

^aDepartment of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

^bDepartment of Biomolecular Engineering Graduate School of Engineering, Tohoku University, 6-6-11 Aoba, Aramaki, Aoba-ku, Sendai 980-8579, Japan

^cCenter for Sustainable Resource Science, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

^dGraduate School of Science, Technology and Innovation, Kobe University, 1-1 Rokkodai, Nada, Kobe 657-8501, Japan

[†]Current address: R. Fujiwara Center for Sustainable Resource Science, RIKEN, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan

Corresponding authors:

* Shuhei Noda, **Email:** shuhei.noda@riken.jp

* Tsutomu Tanaka, **Email:** tanaka@kitty.kobe-u.ac.jp

Abstract

Escherichia coli, the most studied prokaryote, is an excellent host for producing valuable chemicals from renewable resources as it is easy to manipulate genetically. Since the periplasmic environment can be easily controlled externally, elucidating how the localization of specific proteins or small molecules in the periplasm affects metabolism may lead to bioproduction development using *E. coli*. We investigated metabolic changes and its mechanisms occurring when specific proteins are localized to the *E. coli* periplasm. We found that the periplasmic localization of β -glucosidase promoted the shikimate pathway involved in the synthesis of aromatic chemicals. The periplasmic localization of other proteins with an affinity for glucose-6-phosphate (G6P), such as inactivated mutants of Pgi, Zwf, and PhoA, similarly accelerated the shikimate pathway. Our results indicate that G6P is transported from the cytoplasm to the periplasm by the glucose transporter protein EIICB^{Glc}, and then captured by β -glucosidase.

Keywords

Periplasm, shikimate pathway, *Escherichia coli*, glucose-6-phosphate, phosphotransferase system

Introduction

Technologies allowing for the bioproduction of fuels and chemicals from renewable resources are in great demand. Extensive research efforts aim to develop technologies to produce aromatic compounds for chemical, pharmaceutical, food, feed, and other industries (Fujiwara et al., 2018; Shen et al., 2017; Sun et al., 2016). In *Escherichia coli*, most aromatic chemicals are synthesized endogenously through the shikimate pathway (Noda and Kondo, 2017). Production of shikimate derivatives could be increased by promoting the shikimate pathway (Nakagawa et al., 2011) and/or disrupting the competing pathways (Niu et al., 2019; Noda et al., 2016; Rodriguez et al., 2013). For example, salicylate, an important chemical in the pharmaceutical industry, is a main shikimate pathway derivative (Noda et al., 2016). Phenol and styrene, which have major industrial applications worldwide, can also be produced using microbial catalysis under moderate reaction conditions (Chung et al., 2015; Lian et al., 2016). The aromatic amino acids L-phenylalanine (Phe), L-tyrosine (Tyr), and L-tryptophan (Trp) are produced via enzymatic reactions from chorismate, the end product of the shikimate pathway (Lütke-Eversloh and Stephanopoulos, 2007; Olson et al., 2007; Wu et al., 2018). Important dicarboxylic acids as raw materials for polymers with high industrial demand, such as *cis,cis*-muconic acid (MA) and maleate, could also be obtained from chorismate (Fujiwara et al., 2018; Noda et al., 2016; Thompson et al., 2018; Zhang et al., 2015). Therefore, the microbial production of shikimate pathway derivatives represents a potentially game-changing technology for both the environment and economy.

The periplasm is a space between the inner and outer membranes of gram-negative bacteria, which generally contains a peptidoglycan layer. Estimates of periplasmic thickness in *E. coli* vary from 10 to 50 nm (Sochacki et al., 2011), accounting for approximately 20%–40% of their cellular volume (Stock et al., 1977). The periplasm of *E. coli* contains > 60 known proteins, including amino acid-, sugar-, vitamin-, and ion-binding proteins; degradative enzymes (phosphatases, proteases, and endonucleases); and antibiotic detoxifying enzymes. (Schmidt T., 2019). In bioproduction using bacteria, the periplasm is used as a localization site for proteins during heterologous protein production (Bodelón et al., 2013; Fernández, 2004; Malherbe et al., 2019) or as a localization site for hydrolases to provide bacteria the ability to use carbon sources that are originally unavailable (Georgiou and Segatori, 2005; Kurumbang et al., 2020). In *E. coli*, periplasmic expression of Tfu0937, a β -glucosidase (BGL) from *Thermobifida fusca* YX that hydrolyzes β -glycosidic bonds in cellobiose and cello-oligosaccharides, has been used for the production of valuable chemicals from cello-oligosaccharides (Tanaka et al., 2011). For instance, periplasmic BGL expression has been used to produce mevalonate and 1,2-propanediol from cellobiose (Nonaka et al., 2021; Satowa et al., 2020). Although periplasmic protein expression methods are now well-established (Gonzalez-Perez et al., 2021; Mirzadeh et al., 2020), the mechanisms by which periplasmic expression of proteins such as BGL affect metabolism remain largely undetermined.

Here, we demonstrate that the periplasmic expression of BGL or inactivated BGL increased L-phenylalanine (Phe) production from glucose. We investigated factors related to this phenomenon and found that EIICB^{Glc} and glucose-6-phosphate (G6P) were

involved. *E. coli* with heterologous BGL expression exhibited accumulation of intracellular phosphoenolpyruvate (PEP), which accelerates the shikimate pathway. We hypothesized that G6P is transported from the cytoplasm to the periplasm by EIICB^{Glc} and then captured by BGL in the periplasm. We confirmed that periplasmic expression of other proteins that capture G6P also increases Phe production, thus supporting our hypothesis. Furthermore, the production of other shikimate pathway derivatives, Tyr and MA, was also increased by the method expressing BGL in the periplasm.

Material and methods

Media

Lysogeny broth (LB) medium comprising 10 g L⁻¹ tryptone, 5 g L⁻¹ yeast extract, and 5 g L⁻¹ NaCl was used for preculture. For L-phenylalanine and MA production, a modified M9 medium was used. The M9 minimal medium (0.5 g L⁻¹ NaCl, 17.1 g L⁻¹ Na₂HPO₄•12H₂O, 3 g L⁻¹ KH₂PO₄, 1 g L⁻¹ NH₄Cl, 246 mg L⁻¹ MgSO₄•7H₂O, 14.7 mg L⁻¹ CaCl₂•2H₂O, 2.78 mg L⁻¹ FeSO₄•7H₂O, 10 mg L⁻¹ thiamine hydrochloride) was supplemented with 5 g L⁻¹ yeast extract, 10 mM sodium pyruvate, a carbon source (20 g L⁻¹ glucose, xylose or fructose), 40 mg L⁻¹ L-tyrosine and 40 mg L⁻¹ of L-tryptophan. The inclusion of L-tyrosine and L-tryptophan aimed to prevent auxotrophic effects of the ATCC31882 strain on these amino acids. For L-tyrosine production, a modified M9 medium supplemented with 100 mg L⁻¹ L-phenylalanine without adding L-tyrosine was used. When comparing the capability of glucose and G6P as carbon sources, 55.5 mM of these components were added to this modified M9 medium. For L-tyrosine production, a modified M9 medium supplemented with 10 g L⁻¹ glucose was instead used. Ampicillin,

kanamycin or chloramphenicol were added to the media with a final concentration of 100, 20 or 30 mg L⁻¹, respectively.

Culture conditions

Engineered strains were precultured in test tubes containing LB medium for one day at 37°C with shaking at 220 rpm. Each preculture medium was centrifuged at 12,000 × g for 3 min and the pellet washed with M9 minimal medium without sugars. The preculture was then used to inoculate the appropriate media at an initial optical density of 0.1, measured at a wavelength of 600 nm (OD₆₀₀). As needed, 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was also added to the media. Test tube-scale cultures were incubated at 37°C with shaking at 220 rpm.

Strains and plasmid construction

Supplementary Table 1 lists the strains and plasmids used in this study. *Escherichia coli* NovaBlue competent cells (Novagen, Cambridge, MA, USA) were employed for gene cloning. We conducted polymerase chain reaction (PCR) using KOD FX Neo (Toyobo, Osaka, Japan) and synthesis of custom DNA oligonucleotide primers using Invitrogen custom DNA oligos (Thermo Fisher Scientific, Tokyo, Japan) (Supplementary Table 2). The In-Fusion HD Cloning Kit (Takara Bio, Shiga, Japan) was used to assemble multiple DNA fragments and circularize linearized DNA fragments. Supplementary Table 3 summarizes the detailed construction methods for all plasmids.

Deletion of chromosomal genes

Supplementary Table 1 lists the plasmids used to delete chromosomal genes. The deletion strains were constructed in this study using the CRISPR-Cas two-plasmid system (Jiang *et al.*, 2015). A pCas plasmid was first introduced in the parental strain. Subsequently, an appropriate pTΔ plasmid was introduced in the pCas-harboring strain, followed by overnight incubation in LB medium with 10 g L⁻¹ arabinose as an inducer for λ-Red, without kanamycin or spectinomycin. The culture was plated on LB agar containing 50 mg L⁻¹ kanamycin and 100 mg L⁻¹ spectinomycin after culture recovery. Targeted gene deletion was confirmed using colony PCR and the plasmids pCas and pTΔ were eliminated from the bacterial target-gene-deficient strain. All fragments inserted in the plasmids to inactivate respective genes were amplified using colony PCR, employing the *E. coli* MG1655 strain as a template and appropriate primer, as listed in Supplementary Table 2. The plasmids pTΔptsG, pTΔcrr, pTΔpheA, pTΔsgrS, and pTΔpgi were used to delete *ptsG*, *crr*, *pheA*, *sgrS*, and *pgi*, respectively. The plasmid pTtrpE::tyrfbr was used to insert *tyrA*^{fbr} in the *trpE* gene loci and pTptsG::galP-*glk* to insert *galP-glk* in the *ptsG* gene loci.

Transformation of *E. coli* strains

Escherichia coli strains were transformed using electroporation with a 1350 kV, 600 Ω, and 10 μF electric pulse in a 0.1-cm cuvette using a Gene Pulser (Bio-Rad Laboratories, Hercules, CA, USA).

Analytical methods

Cell growth was analyzed by measuring OD₆₀₀ using an UVmini-1240 spectrophotometer (Shimadzu Corporation, Kyoto, Japan). Glucose, xylose and fructose levels were measured using a Prominence high-performance liquid chromatography (HPLC) system (Shimadzu Corporation) equipped with a Shodex SUGAR KS-801 column (grain diameter, 6 µm; L × I.D., 300 × 8.0 mm; Showa Denko, Tokyo, Japan). Water was used as the mobile phase with a flow rate of 0.8 mL min⁻¹ and the column was maintained at 50°C. The HPLC profile was monitored using a refractive index detector.

L-phenylalanine and L-tyrosine were analyzed using an HPLC system equipped with a PBr column (grain diameter, 5 µm; L × I.D., 250 × 4.6 mm; Nacalai Tesque, Inc., Kyoto, Japan). A dual-solvent system was used, in which solvent A was 0.2% phosphate buffer and solvent B methanol. The mobile phase flow rate was 1.0 mL min⁻¹ and the column was maintained at 40°C. A gradient was initiated with an 80:20 mixture of solvents A and B (0–15 min), replaced by a 50:50 mixture of solvents A and B (15–20 min), and subsequently by an 80:20 mixture of solvents A and B (20–25 min). The HPLC profile was monitored using an ultraviolet-visible (UV-Vis) detector at a wavelength of 240 nm.

PEP, pyruvate, acetyl coenzyme A (CoA), G6P, F6P, F16BP, 6PG, Ru5P, Ro5P, E4P, S7P and 3PG + 2PG were analyzed using liquid chromatography–mass spectrometry (LC–MS), as detailed in the Metabolome analysis section.

Metabolome analysis

Metabolome analysis was conducted as previously reported with some modifications (Shirai *et al.*, 2013). Briefly, cells were cultured in M9Y medium supplemented with 20 g L⁻¹ glucose until a mid-logarithmic growth phase was reached, corresponding to 18 h for EΔHI0, BPΔHI1, EΔHIG0 and BPΔHIG1. Afterwards, culture broth was harvested via rapid filtration. Filtered cells were dropped into cold methanol to rapidly quench metabolic flow and their intracellular metabolites were extracted in a 2.5:2.5:1 (v/v/v) CHCl₃:CH₃OH:H₂O mixture. Following centrifugation at 15,000 × g at 4°C for 15 min, the upper phase was collected. Metabolites were quantified by HPLC coupled with an electrospray ionization tandem mass spectrometry (LCMS-8040 triple quadrupole LC/MS/MS spectrometer; Shimadzu Corporation), using the Method Package for Primary Metabolites.

Measurement of BGL enzymatic activity

Each strain was cultured in LB medium at 37°C for 24 h. The periplasmic activity of BGL was evaluated using *p*-nitrophenyl-β-D-glucopyranoside (pNPG; Nacalai Tesque) as a substrate. One unit of BGL activity was defined as the amount of enzyme that produced 1 μmol min⁻¹ of *p*-nitrophenol at 37°C and pH 5.0. The amount of *p*-nitrophenol produced was determined using a Synergy H1 microplate reader (BioTek Japan, Tokyo, Japan) at a wavelength of 400 nm. Apparent inhibition constants were calculated by curve-fitting the experimental values to the Morrison equation (Eq. 1) (Morrison, 1969).

$$\frac{v_i}{v_0} = 1 - \frac{([E] + [I] + K_{i-app}) - \sqrt{([E] + [I] + K_{i-app})^2 - 4[E][I]}}{2[E]} \quad (\text{Eq. 1})$$

199

200 [E], enzyme concentration; [I], inhibitor concentration; K_{i-app} , apparent inhibition
 201 constant; v_0 , initial rate observed in the absence of the inhibitor; v_i , initial rate observed
 202 in the presence of the inhibitor.

203

204 **Immunoblotting**

205 Each strain was cultured at 37°C for 24 h in a modified M9 medium supplemented with
 206 glucose. The cells were subsequently centrifuged at 12,000 ×g at 4°C for 5 min, washed
 207 and resuspended in 500 µL of phosphate-buffered saline at pH 7. Afterwards, they were
 208 disrupted using a Micro Smash MS-100R (Tomy Seiko, Tokyo, Japan). Sodium dodecyl
 209 sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) buffer (2% SDS, 10% glycerol,
 210 5% 2-mercaptoethanol, 0.002% bromophenol blue, 0.125 M Tris-HCl; pH 6.8) was added
 211 to the supernatant, followed by boiling at 95°C for 5 min. Proteins were analyzed by
 212 SDS-PAGE using an e-PAGEL (Atto, Tokyo, Japan), including dual-color prestained
 213 Precision Plus protein standards (Bio-Rad Laboratories, Richmond, CA, USA) to serve as
 214 molecular weight markers. Proteins were electroblotted with an Amersham Hybond-P
 215 system (GE Healthcare, IL, USA) and incubated with an ANTI-FLAG M2 monoclonal
 216 antibody (Sigma-Aldrich, MO, USA) followed by an anti-rabbit IgG (Fc) AP conjugate
 217 (Promega Corp., Madison, WI, USA). Relative expression levels were calculated using
 218 NIH ImageJ v.1.8.0 software (<http://rsbweb.nih.gov/ij>).

219

Measurement of surface plasmon resonance

The interaction between BGL and the glucose or G6P analytes was determined by SPR spectroscopy (Biacore T200; GE Healthcare). β -glucosidase was immobilized on a CM5 sensor chip with up to 8000 resonance units using 10 mM sodium acetate buffer (pH 4.2) containing 160 $\mu\text{g mL}^{-1}$ BGL, delivered at a flow rate of 5 $\mu\text{L min}^{-1}$ at 25°C. The running buffer was phosphate-buffered saline containing 0.005% Tween-20 and the analytes (glucose or G6P) were injected for 300 s at concentrations of 391–200 mM.

Quantification of mRNA transcription levels using real time PCR

The transcriptional expression of *uhpT* was quantified in each strain using real time PCR. Briefly, total RNA was isolated from individual cultures using a NucleoSpin RNA column (Takara Bio) according to the manufacturer's instructions. Reverse transcription and quantitative real time PCR were then performed using an Mx3005P real time QPCR system (Agilent Technologies, Santa Clara, CA, USA) with an RNA-direct SYBR green real time PCR master mix (Toyobo). Supplementary Table 2 lists the primer pairs. The normalized transcriptional level of each mRNA was lastly calculated and compared with the housekeeping gene *mdoG* (encoding glucan biosynthesis protein G) (Heng *et al.*, 2011).

Jar fermenter cultivation

Batch scale cultures were performed in 1.0 L jar fermenters with a 400 mL working volume at 37°C. For Phe production at this scale, we used the medium containing 3.29 g L^{-1} NaCl, 1.64 g L^{-1} KCl, 10 g L^{-1} $(\text{NH}_4)_2\text{SO}_4$, 10 g L^{-1} $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 14.7 mg L^{-1}

243 $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, 2.78 mg L^{-1} $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$, 10 mg L^{-1} thiamine hydrochloride, 20 g L^{-1}
244 yeast extract, 50 g L^{-1} glucose, 100 mg L^{-1} L-tyrosine, 100 mg L^{-1} L-tryptophan, and 100
245 mg L^{-1} ampicillin. The medium (400 mL) in the jar fermenter was inoculated with
246 preculture medium to an initial OD_{600} of 0.03. DO was maintained at 2.04 p.p.m. by
247 automatically controlling the agitation speed from 200 to 800 r.p.m and supplementing
248 with air at 0.40 L min^{-1} . The pH was maintained above 6.8 with the automatic addition of
249 10% ammonia solution.

Results

BGL expression in the *E. coli* periplasm increases Phe production

The periplasmic expression of BGL is often employed in bioproduction, with cellobiose or cello-oligosaccharide as carbon sources (Georgiou and Segatori, 2005; Kurumbang et al., 2020; Nonaka et al., 2021; Satowa et al., 2020; Tanaka et al., 2011). Serendipitously, we found that periplasmic BGL expression altered the Phe production titer when glucose was used as a carbon source, even though glucose is not a BGL substrate. We thus focused on investigating how periplasmic expression of BGL affects Phe production.

We derived BGL from the *T. fusca* YX's Tfu0937 protein (UniProt Q47RE2), which exhibits enzymatic activity in *E. coli* (Soma et al., 2012; Tanaka et al., 2011). To induce periplasmic localization of Tfu0937, we used cell surface display, which anchors a target protein to the outer cell membrane, and signal sequence-mediated transport strategies.

The C-terminus of the anchor protein Blc (UniProt P0A901), a lipoprotein localized to the outer cell membrane that is exposed to the periplasm, was fused to the N-terminus of Tfu0937, resulting in the periplasmic localization of Tfu0937 (Tanaka et al., 2011).

Alternatively, the PelB signal peptide corresponding to the first 22 residues of pectate lyase B from *Erwinia carotovora* (UniProt P0C1C1) (Choi and Lee, 2004) was fused to the N-terminus of Tfu0937, thereby facilitating its transport to the periplasm without anchoring.

Phenylalanine-overproducing *E. coli* strain ATCC31882 was used as the parent strain for Phe production (<https://www.atcc.org/products/all/31882.aspx>, ATCC). We constructed four strains (named BD1, BP1, BC1, and E0). The E0 strain, harboring a high-copy

empty vector, was used as control. Strain BD1 harbored a high-copy plasmid expressing Tfu0937 fused with Blc (B-Tfu), strain BP1 harbored a high-copy plasmid expressing Tfu0937 fused with the PelB signal peptide (P-Tfu), and strain BC1 harbored a high-copy plasmid expressing intact Tfu0937, which is localized in the cytoplasm. After 48 h of cultivation using glucose as a substrate, BD1 and BP1 produced 1.46 ± 0.05 and 2.19 ± 0.10 g/L of Phe, respectively, which were 1.49- and 2.23 times higher than E0 (control strain; 0.98 ± 0.03 g L⁻¹), respectively (Fig. 1A). By contrast, compared with E0, BC1 produced 1.04 ± 0.21 g L⁻¹ of Phe. There was no significant difference in cell growth (OD₆₀₀) of these four strains after 48 h of culture (Fig. S1A). Figure S1B shows specific BGL activity per cell density. There was no significant difference in specific BGL activity per cell density of BD1, BP1, and BC1. We confirmed Tfu0937 in strains by immunoblotting. Whole-cell extracts from BC1, BD1, and BP1 exhibited Tfu0937, B-Tfu, and P-Tfu expressions, respectively, at comparable levels (Fig. 1B). As described in a previous report, we observed in B-Tfu-expressing BD1 a band corresponding to the mass of unfused Tfu0937 (Ikeda et al., 2013). B-Tfu and P-Tfu were detected in periplasmic extracts of BD1 and BP1, respectively, at levels comparable to those in whole-cell extracts. However, Tfu0937 in the BC1 periplasmic extract was significantly decreased compared with that in the whole-cell extract (Fig. 1B). These results suggested that BGL localization to the periplasm positively affected Phe production, regardless of the localization method.

Next, we investigated how changing the number of plasmid copies would affect the Phe production. We constructed low- and medium-copy number plasmids for B-Tfu

expression that were introduced into ATCC31882, generating the strains BD1L (the low-copy plasmid) and BD1M (the medium-copy plasmid). We used the strains E0L and E0M, containing low- and medium-copy empty plasmids, respectively, as controls. Figure 1C shows the relative amount of Phe produced from glucose in strains with different copy numbers of plasmids. Phenylalanine production was increased 1.21, 1.39 and 1.48 times in strains BD1L, BD1M and BD1 (high-copy), respectively. We confirmed a positive correlation between the copy number and BGL activity or expression (Fig. 1D, S1C), indicating that Phe production and the B-Tfu expression levels exhibit a positive, not directly proportional correlation. We confirmed the correlation between BGL activity and Phe production. Based on these results, we used a high-copy plasmid as the expression vector in the following experiments. We constructed a strain, referred to as BD2, expressing an inactivated mutant BGL (Tfu0937^{E388A}) fused with Blc (B-Tfu^{E388A}). As Glu388 is a putative nucleophilic residue required for enzymatic activity in Tfu0937, the Glu388Ala mutant (Tfu0937^{E388A}) is rendered inactive (Chir et al., 2011; Spiridonov and Wilson, 2001). Although the BD2 strain showed no BGL activity (Fig. S1C), expectedly, it produced $1.86 \text{ g L}^{-1} \pm 0.07 \text{ g L}^{-1}$ Phe from glucose, which was 1.90 times higher than the control strain (E0) (Fig. S1D). The periplasmic localization of inactivated BGL also had a positive effect on Phe production, indicating that BGL enzymatic activity was not required to increase Phe production. Thus, we suspected that an unknown mechanism could underlie the increased Phe production driven by periplasmic BGL localization.

Periplasmic BGL localization does not affect Phe production in EIIC^{Glc} domain-deficient strains

The phosphotransferase (PTS) system simultaneously mediates sugar transport and phosphorylation (Fig. 2A). Glucose uptake in *E. coli* involving the PTS system comprises four proteins located in either the inner membrane or cytoplasm: enzyme I (EI, encoded by *ptsI*), HPr (encoded by *ptsH*), enzyme IIA (EIIA, encoded by *crr*) and EIICB^{Glc} (encoded by *ptsG*). The enzymes EI, HPr and EIIA are cytoplasmic, whereas EIICB^{Glc} is a transmembrane protein with two domains: an N-terminal membrane-spanning EIIC^{Glc} domain containing a carbohydrate-binding site and a C-terminal cytoplasmic EIIB^{Glc} domain containing a phosphorylation site (Cys421). EI and HPr are involved in the transport of numerous sugars, whereas EIIA, EIIB and EIIC are sugar-specific. In the PTS system, 1 mol PEP is converted to 1 mol pyruvate during the transport of 1 mol glucose into the cell. The phosphate group of PEP is transferred to the EI, then relayed to the HPr and EIIB domains. Glucose is subsequently transported from the periplasm to the cytoplasm via the EIIC^{Glc} domain of EIICB^{Glc} and simultaneously converted to G6P via phosphoryl transfer from the phosphorylated EIIB^{Glc} domain. Although the PTS system is the main glucose transport system in bacteria, *E. coli* also uses the galactose permease/glucokinase (GalP/Glk) system (Fig. 2A). The GalP is a galactose permease with 12 transmembrane α helices (Zheng et al., 2010) involved in the transport of galactose, its main substrate, and glucose. Its expression is repressed when *E. coli* is grown in the presence of glucose (Hernández-Montalvo et al., 2003). The Glk, a glucokinase, localizes to the cytoplasm where it catalyzes ATP-dependent glucose phosphorylation (Hernández-Montalvo et al., 2003).

341

342 The PTS system is a major metabolic reaction that competes with the shikimate pathway
343 for PEP consumption (Fujiwara et al., 2020). Replacing the PTS system with another
344 sugar-specific transport system, such as the GalP/Glk system, is often employed to
345 increase the amount of PEP available for the shikimate pathway (Hernández-Montalvo et
346 al., 2003). Previously, we constructed an ATCC31882-derived strain named CFT1, in
347 which two PTS-related genes, *ptsI* and *ptsH*, were replaced with the GalP/Glk system
348 (Noda et al., 2016). To investigate the effects of periplasmic BGL localization in our
349 metabolically engineered system, we evaluated Phe production using the CFT1 strain.
350 The BD Δ HI1 (CFT1 expressing B-Tfu) and BP Δ HI1 (CFT1 expressing P-Tfu) strains
351 produced 3.51 ± 0.10 and 3.44 ± 0.12 g/L Phe (Fig. 2B), which were 1.30- and 1.27 times
352 higher, respectively, than the E Δ HI0 strain (CFT1 harboring an empty vector) ($2.70 \pm$
353 0.24 g L⁻¹ Phe). Using glucose as the sole carbon source in BP Δ HI1 strains, the Phe
354 yields was 0.24 mol mol⁻¹ close to the highest values reported previously (0.26 mol mol⁻¹
355 in a fed-batch culture, 0.23 mol mol⁻¹ in batch culture) (Zhou et al., 2010). In BD Δ HI1
356 and BP Δ HI1 strains, intracellular PEP increased by 1.2 and 2.6 times, respectively,
357 compared to the E Δ HI0 strain (Fig. S2A, B). Contrastingly, intracellular pyruvate and
358 acetyl-CoA levels were decreased in BD Δ HI1 and BP Δ HI1 strains compared to the
359 E Δ HI0 strain (Fig. S2A, B). This finding suggested that periplasmic BGL localization
360 increased PEP accumulation in *ptsHI*-deficient strains, an effect that was most
361 pronounced in BP Δ HI1. We thus used the PelB signal peptide to drive periplasmic
362 protein localization in subsequent experiments.

Considering that EI and HPr (lacking in the strain CFT1) are localized in the cytoplasm, we suspected that these proteins are not involved in this phenomenon. To determine the contribution of other PTS proteins in improving Phe production, we constructed strains that disrupted other PTS proteins *crr* or *ptsG*, which encode EI_{IA} (cytoplasm) and EI_{ICB}^{Glc} (transmembrane), respectively, in CFT1 strain. We named the resultant strains CFT1Δ*crr* and CFT1Δ*ptsG*. We cultured BPΔHIC1 (CFT1Δ*crr* expressing P-Tfu), EΔHIC0 (CFT1Δ*crr* harboring an empty vector), BPΔHIG1 (CFT1Δ*ptsG* expressing P-Tfu), and EΔHIG0 (CFT1Δ*ptsG* harboring an empty vector) in a medium containing glucose as the sole carbon source. The BPΔHIC1 strain produced $3.00 \pm 0.19 \text{ g L}^{-1}$ of Phe, 1.57 times higher than that produced by the EΔHIC0 strain ($1.91 \pm 0.13 \text{ g L}^{-1}$; Fig 2C). By contrast, BPΔHIG1 produced a similar amount of Phe ($2.34 \pm 0.12 \text{ g L}^{-1}$) as EΔHIG0 ($2.39 \pm 0.25 \text{ g L}^{-1}$; Fig. 2C), indicating that *ptsG* was required for periplasmic BGL localization to facilitate increased Phe production in the CFT1-derived strain. BPΔHIG1 exhibited a significant decrease in intracellular PEP compared with the EΔHIG0 control (Fig. S2C), contrary to the effect observed between BPΔHI1 and EΔHI0 shown in Figure S2B. We found no significant differences in intracellular pyruvate and acetyl-CoA levels between EΔHIG0 and BPΔHIG1 (Fig. S2C), which also differed from the result shown in Figure S2B. Cumulatively, these results indicate that *ptsG* is a key factor mediating the BGL-dependent increase in Phe production.

To further elucidate the effects of *ptsG* disruption, we constructed the strain disrupting *ptsG* in the ATCC31882 background and named it ATCC31882Δ*ptsG*. We cultured BPΔG1 (ATCC31882Δ*ptsG* expressing P-Tfu) and EΔG0 (ATCC31882Δ*ptsG* harboring

an empty vector) using glucose as the sole carbon source. Consistent with our previous results, the EΔG0 and BPAΔG1 strains produced 1.57 ± 0.06 and 1.54 ± 0.09 g L⁻¹ of Phe, respectively, with no significant difference (Fig. 2D). We found no significant differences in intracellular PEP, pyruvate, and acetyl-CoA levels between EΔG0 and BPAΔG1 (Fig. S2D). These results strongly support that *ptsG* is a key factor in this phenomenon. We constructed an ATCC31882 strain containing the endogenous EIICB^{Glc} protein inactivated via point mutation and named it C421S. During glucose transport, EIICB^{Glc} receives a phosphate group from EIIA on Cys421, which allows it to serve as a phosphate group donor for glucose; therefore, we eliminated the phosphorylation capability of EIICB^{Glc} by creating the Cys421Ser mutant. The strain BPC^{C421S}1 (C421S expressing P-Tfu) produced 2.03 ± 0.03 g L⁻¹ of Phe, 1.36 times higher than that produced by E^{C421S}0 (C421S harboring an empty vector) (Fig. 2D). These results indicate that although EIICB^{Glc} presence is required for periplasmic BGL-dependent Phe production, phosphorylation of Cys421 is unnecessary. To investigate specific roles of the EIIB^{Glc} and EIIC^{Glc} domains in this phenomenon, we constructed two strains derived from ATCC31882Δ*ptsG*—strain dGB (ATCC31882Δ*ptsG* harboring pZA23-EIIB^{Glc}) expressed only the EIIB^{Glc} domain, strain dGC (ATCC31882Δ*ptsG* harboring pZA23-EIIC^{Glc}) expressed only the EIIC^{Glc} domain. Strains EdGB0 (dGB harboring an empty vector) and BPdGB1 (dGB expressing P-Tfu), which express only the EIIB^{Glc} domain, produced Phe with insignificant difference in production (Fig. 2E). By contrast, strains EdGC0 (dGC harboring an empty vector) and BPdGC1 (dGC expressing P-Tfu), which express only the EIIC^{Glc} domain, produced 0.73 ± 0.03 and 1.85 ± 0.07 g L⁻¹ of Phe, respectively, and the titer in BPdGC1 was 2.5 times higher than that in the EdGC0

control (Fig. 2E). These results demonstrate that the EIIC^{Glc} domain is specifically necessary for the periplasmic BGL-dependent increase in Phe production, unlike the EIIB^{Glc} domain.

G6P—a key metabolite, as demonstrated via metabolome analysis

Our results indicate that EIICB^{Glc}, encoded by *ptsG*, is a key factor in increasing Phe production. However, the direct interaction between B-Tfu and the EIIC^{Glc} domain is likely impossible because B-Tfu is anchored at the cell's outer membrane, whereas EIIC^{Glc} domain is present on the cell's inner membrane. Therefore, we hypothesized that EIIC^{Glc} domain could act as a transporter for another key metabolite that would interact with B-Tfu in the periplasmic space.

To identify metabolites involved in periplasmic BGL-dependent Phe production, we cultured EΔHI0 and the strain expressing P-Tfu derived from CFT1 (BPΔHI1) using glucose as a substrate and measured the intracellular concentration (including cytosol and periplasm) of glycolysis and pentose phosphate pathway (PPP) metabolites (Fig. 3A, B). Although intracellular levels of 6-phosphogluconate and erythrose-4-phosphate were slightly decreased in BPΔHI1 compared with EΔHI0, most other glycolysis and pentose phosphate pathway (PPP) metabolites were also not significantly different between the strains or were decreased in BPΔHI1 (Fig. 3B). Interestingly, intracellular G6P concentration was increased by 2.25 times in BPΔHI1 compared with that in EΔHI0 (Fig. 3B). Moreover, we found no significant differences in the G6P concentration between EΔHIG0 and BPΔHIG1 (CFT1Δ*ptsG* expressing P-Tfu) (Fig. S3A).

432

433 Metabolome analysis suggested that G6P was a candidate metabolite potentially involved
434 in improving periplasmic BGL-mediated Phe production. To confirm this, we examined
435 Phe production using non-G6P sugars (xylose or fructose) as carbon sources. In the *E.*
436 *coli* catabolic pathway, glucose entering the cell through the PTS or GalP/Glk systems is
437 converted to G6P to initiate glycolysis. Both G6P and F6P are readily interconverted by
438 G6P isomerase. Xylose is transported into the cell by xylose-specific ATP-binding
439 cassette transporters or the xylose-proton symporter and converted to xylulose, which is
440 subsequently converted to xylulose-5-phosphate entering PPP. Fructose is further
441 transported by the fructose-specific PTS and converted to fructose-1-phosphate (F1P),
442 which, in turn, is converted to F16BP entering glycolysis (Fig. S3B). When xylose or
443 fructose are used as a carbon source, carbon flows into G6P and F6P in low proportions
444 due to its utilization via PPP or gluconeogenesis. Therefore, the xylose and fructose used
445 as a carbon source are catabolized with less conversion to G6P, reducing the intracellular
446 G6P concentration. When xylose or fructose were used as carbon source, BP Δ H11
447 produced 0.49 ± 0.02 and 0.21 ± 0.06 g L⁻¹ of Phe (Fig. S3C), respectively, which is
448 comparable to the amounts produced by the control (E Δ H10) (0.52 ± 0.05 and 0.21 ± 0.02
449 g L⁻¹, respectively). The intracellular G6P concentrations did not significantly differ
450 between B Δ H11 and E Δ H10 (Fig. S3D, E). This observation suggested that G6P is a key
451 metabolite in the periplasmic BGL localization as proposed (Fig. 3C).

452

453 For G6P to act as a key metabolite, its interaction with BGL is required. We measured the
454 fractional enzymatic activity of BGL in the presence of excess G6P or glucose and found

that it decreased more in response to G6P compared with excess glucose. The apparent inhibition constants were 595 and 295 mM for glucose and G6P, respectively (Fig. 3D). This finding indicated that Tfu0937 has a higher affinity for G6P than glucose, although Tfu0937 has no catalytic activity against G6P. We used surface plasmon resonance to measure the interaction between BGL and glucose or G6P. The sensorgrams indicate that although BGL interacts with both metabolites, it exhibits a higher affinity for G6P than glucose (Fig. 3E). These results support our hypothesis that BGL interacts with G6P in the periplasm.

G6P secretion and accumulation in the periplasm

Metabolome analysis revealed that intracellular G6P levels, comprising both cytoplasmic and periplasmic fractions, increased significantly with periplasmic BGL localization. To ensure that the EIIC^{Glc} domain functions as a cytoplasm-to-periplasm G6P transporter, quantifying G6P levels in the periplasm exclusively would be required. However, we were unable to quantify the periplasmic G6P, while excluding cytoplasmic content. We thus measured the messenger RNA (mRNA) of *uhpT* as a strong indicator of periplasmic G6P concentration. Expression of the hexose phosphate transporter (UhpT) is strictly controlled by the UhpABC regulatory system (also named the Uhp system, Fig. 4A). A non-linear positive correlation also exists between the induction of *uhpT* transcription and G6P concentration in the medium (Västermark and Saier, 2014; Verhamme et al., 2002, 2001). When UhpC senses periplasmic G6P, the UhpBC complex changes conformation, leading to the autophosphorylation of UhpB (P-UhpB) using ATP as the phosphoryl group donor (Västermark and Saier, 2014). The phosphoryl group of P-UhpB is then

transferred to UhpA, which binds to the transcriptional regulatory promoter region of *uhpT*, enhancing *uhpT* transcription (Västermark and Saier, 2014; Verhamme et al., 2002, 2001). We determined whether the presence of G6P in the medium increased *uhpT* transcription levels, as previously reported (Verhamme et al., 2002). We observed a non-linear positive correlation between *uhpT* transcription levels in ATCC31882 and the quantity of G6P supplemented in the medium (Fig. 4B). Therefore, we were able to successfully use *uhpT* transcription level to measure periplasmic G6P concentration.

We cultured E0, EΔG0, and E^{C421S}0 strains using glucose as the carbon source and measured the *uhpT* transcription levels. Figure 4C shows the relative *uhpT* transcription levels in strains E0, EΔG0, and E^{C421S}0. The *uhpT* transcription in EΔG0 was significantly lower than that in the control (E0), whereas the *uhpT* transcription in E^{C421S}0 was comparable to that in E0. Considering that E^{C421S}0 expressed a variant EIICB^{Glc} protein with an inactivated phosphate donor domain (EIIB^{Glc} domain) and native membrane-spanning domain (EIIC^{Glc} domain), these results support our hypothesis that the EIIC^{Glc} domain acts as a G6P transporter regardless of whether the EIIB domain exhibits phosphorylation activity.

Second, we investigated how the periplasmic BGL localization affects the periplasmic G6P concentration. The *uhpT* expression levels were compared in the glucose-containing medium between E0 and BP1 or between EΔG0 and BPΔG1. BP1 exhibited significantly higher *uhpT* levels compared with the control (E0), suggesting that periplasmic BGL localization causes periplasmic G6P accumulation (Fig.4D). Alternatively, the *uhpT*

levels were comparable between E Δ G0 and BP Δ G1 (Fig. 4E), suggesting that *uhpT* transcription was not activated by the periplasmic localization of BGL when EIICB^{Glc} was absent and incapable of secreting G6P into the periplasm (Fig. 4C, E).

To investigate further G6P transport via the EIIC^{Glc} domain, we constructed another ATCC31882-derived EIICB^{Glc}-deficient strain, named P2Gs. In the P2Gs strain, *ptsG* was replaced by the *galP-glk* operon and disrupted *sgrS* which encodes a small RNA triggering the degradation of *ptsG* mRNA that can be activated by the accumulation of intracellular G6P (Poddar et al., 2021). This *sgrS* disruption prevented the unintended mRNA degradation when EIIC^{Glc} was overexpressed. We constructed two strains, P2GsE (P2Gs harboring an empty vector) and P2GsC (P2Gs harboring pZA23-EIIC^{Glc}), and cultured them with glucose as a carbon source. The intracellular G6P concentration (including the cytoplasmic- and the periplasmic-G6P) and *uhpT* expression levels were compared between P2GsE and P2GsC in the logarithmic phase (7 h after cultivation). No significant difference could be observed in the intracellular G6P levels between P2GsE and P2GsC (Fig. 4F). This result indicated that the presence or absence of EIIC^{Glc} does not affect the total amount of intracellular G6P. However, *uhpT* expression in P2GsC was 2.82 times higher than in P2GsE (Fig. 4F). This result indicated that overexpressing the EIIC^{Glc} domain increased periplasmic G6P concentration, by transporting G6P from the cytoplasm to the periplasm. We constructed a G6P-accumulating strain by disrupting *pgi* from P2Gs, named P2Gs Δ *pgi*, and confirmed an increase in *uhpT* expression resulting from increased G6P secretion. The strain P2GsC Δ *pgi* (P2Gs Δ *pgi* harboring pZA23-EIIC^{Glc}) was cultured with glucose as a carbon source. The intracellular G6P

concentration in the P2GsC Δ *pgi* strain increased 4.34 times compared to the P2GsC strain, while *uhpT* expression in the P2GsC Δ *pgi* strain was 6.23 times higher than in the P2GsC strain. These results support further our hypothesis that the EIIC^{Glc} domain transports cytoplasmic G6P into the periplasm.

We also investigated the *uhpT* levels in the glucose-containing medium between E Δ HI0 and BP Δ HI1. The *uhpT* level was 4.18-times higher in BP Δ HI1 than in E Δ HI0 (Fig. 4G). In BP Δ HI1, the intracellular G6P (including the cytoplasmic- and the periplasmic-G6P) also increased compared with that in E Δ HI0 (Fig. 3B). Taken together, these results suggest that the BGL-related G6P capture in the periplasm increased the periplasmic G6P concentration, resulting in an increased total amount of intracellular G6P.

Next, we confirmed the effect of the periplasmic G6P, supplied from outside the cell, on Phe production. We cultured strain E0 with G6P as a sole carbon source instead of glucose. Cell growth and Phe production in E0 were at the same levels using G6P as a carbon source or glucose (Fig. S4A, B). Since direct G6P supplementation to the medium did not improve Phe production, we considered the increased periplasmic G6P concentration insufficient to increase Phe production. To clarify the necessary requirements for this phenomenon to activate Phe production, we examined Phe production in strains localizing BGL to the periplasm, BP1 and BP Δ G1, with G6P as a carbon source. The BP1 strain produced 1.3 times higher levels of Phe than the control strain E0 (0.93 ± 0.01 and 0.70 ± 0.02 g L⁻¹, respectively; Fig. S4C). However, no significant difference could be observed between BP Δ G1 and the control strain E Δ G0

(0.47 ± 0.04 and 0.42 ± 0.01 g L⁻¹, respectively; Fig. S4D). This result suggests that the interaction between G6P and BGL is an important factor in increasing Phe production. In addition, it was suggested that the secretion of G6P into the periplasm via the EIIC^{Glc} domain is necessary to increase Phe production even when G6P is sufficiently supplemented in the periplasm from the medium.

Application of other proteins using the proposed mechanism

As we have previously described, the EIIC^{Glc} domain and G6P are key factors for improving Phe production. Our current and previous results on G6P support a leading hypothesis that G6P is transported from the cytoplasm to the periplasm via the EIIC^{Glc} domain and accumulates in the periplasm, where G6P-capturing proteins including BGL localize (Fig. 5A). Based on this mechanism, we assumed that the periplasmic localization of other enzymes with an affinity for G6P would also positively affect Phe production.

We selected three enzymes, G6P isomerase (Pgi), encoded by *pgi*; G6P 1-dehydrogenase (Zwf), encoded by *zwf*; and alkaline phosphatase (PhoA), encoded by *phoA*, and their inactivated mutants as candidates. To facilitate their periplasmic localization, we fused Pgi, Zwf, Pgi^{H386A} (inactivated form), and Zwf^{H239A} (inactivated form) with the PelB signal peptide and named them PelB-Pgi, PelB-Zwf, PelB-Pgi^{H386A}, and PelB-Zwf^{H239A}, respectively. PhoA is a native periplasmic enzyme (Chung Nan Chang et al., 1986). Using ATCC31882, we constructed eight strains localizing these proteins to the cytoplasm or periplasm: PC1 (expressing Pgi), ZC1 (expressing Zwf), PP1 (expressing

570 PelB-Pgi), ZP1 (expressing PelB-Zwf), AP1 (expressing PhoA), PP2 (expressing PelB-
571 Pgi^{H386A}), ZP2 (expressing PelB-Zwf^{H239A}), and AP2 (expressing PhoA^{S124A}, inactivated
572 form). In addition, we constructed a strain expressing green fluorescent protein (GFP), a
573 non-enzymatic protein, in the periplasmic space as a control and called this GP1.

574

575 Because Pgi and Zwf are enzymes involved in glycolysis and PPP, we first examined
576 how overexpressing these enzymes in the cytoplasm affects Phe production. There was
577 no significant difference in Phe production observed between PC1 and E0 (control
578 strain), whereas the strain ZC1 resulted in 1.6 times higher Phe production compared to
579 E0 (Fig. S5A). The Zwf enzyme catalyzes the first reaction of PPP. Because erythrose 4-
580 phosphate, a PPP intermediate, is another starting metabolite for the shikimate pathway,
581 Zwf overexpression might have increased carbon flux into PPP, thereby enhancing the
582 shikimate pathway.

583

584 Figure 5B shows the results for Phe production in the strains PP1, ZP1, AP1, PP2, ZP2,
585 and AP2. The control strain GP1 produced 0.74 ± 0.03 g L⁻¹, whereas strains PP1, ZP1,
586 and AP1 produced 0.62 ± 0.01 , 0.99 ± 0.14 , and 1.16 ± 0.19 g L⁻¹ of Phe, respectively.
587 PP1 produced lesser Phe than the control (E0), and we found no significant difference in
588 Phe production between ZP1 and E0 and between AP1 and E0. Although Zwf
589 overexpression in the cytoplasm in strain ZC1 increased Phe production, the strain ZP1,
590 which overexpresses Zwf in the periplasm, produced the same level of Phe as E0.
591 Contrastingly, strains PP2, ZP2, and AP2, which lacked an enzymatic activity, produced
592 1.69 ± 0.09 , 1.43 ± 0.09 , and 1.64 ± 0.09 g L⁻¹ of Phe, respectively, which was

significantly higher than that produced by E0. Although Zwf expression in the periplasm was similar between ZP1 and ZP2, only ZP2 exhibited increased Phe production compared with E0 (Fig. S5B). These results suggest that the mechanism of increased Phe production in ZP2 is not attributed to increased PPP. In the strains with periplasmic localization of inactivated enzymes (PP2, ZP2, and AP2), the intracellular G6P levels were significantly increased compared with E0 (Fig. S5C). These results suggest that the periplasmic localization of proteins that have affinity for G6P but do not exhibit enzymatic activity for it can facilitate increased Phe production, supporting the hypothesized mechanism (Fig. 5A).

Production of other metabolites using G6P-capturing proteins

To demonstrate our method's ability to increase the production of other shikimate pathway derivatives, we investigated Tyr and MA production using the strains that localize G6P-capturing proteins in the periplasm (Fig. 6A). For Tyr production, we constructed a CFT1-derived strain, named TYR, by disrupting *pheA* encoding chorismate mutase/prephenate dehydratase and inserting *tyrA* into the *trpE* gene locus. We further constructed two TYR-derived strains: TYR1 (expressing B-Tfu) and TYR0 (harboring an empty vector). We cultured TYR1 and TYR0 using glucose as the carbon source. Strains TYR0 and TYR1 produced 2.20 ± 0.03 and 2.73 ± 0.05 g L⁻¹ of Tyr, respectively, while Tyr production was 1.24 times higher in TYR1 compared to TYR0 (Fig. 6B). In the strain TYR1, Tyr yield from glucose was 0.15 mol mol⁻¹. In the Tyr production, two bottleneck reactions were identified in the shikimate pathway (Juminaga et al., 2012). In this study, TYR1 strain was not modified to relieve those bottlenecks. However, the technique of

expressing G6P-capturing protein in the periplasm is compatible with traditional metabolic engineering techniques, such as relieving bottlenecks; thus, we believe that Tyr yield could be increased in TYR1-derived strains by optimizing the shikimate pathway.

For MA production, we selected the MA synthesis pathway that starts from 3-dehydroshikimate (DHS), a shikimate pathway intermediate. In this pathway, which has the highest theoretical yield among all MA synthetic pathways, DHS is converted to protocatechuate (PCA) by DHS dehydratase (*aroZ*), then PCA is converted to catechol (CA) by PCA decarboxylase (*aroY*), and finally CA is converted to MA by CA 1,2-dioxygenase (*catA*) (Fujiwara et al., 2020). We first constructed the CFT1 Δ *pheA* strain derived from CFT1 by disrupting *pheA*, then the CFT1 Δ *pheA*MA strain by introducing CFT1 Δ *pheA* into the MA synthesis pathway. We also constructed two CFT1 Δ *pheA*MA-derived strains: MA1 (expressing P-Tfu) and MA0 (harboring an empty vector). Finally, we cultured MA1 and MA0 using glucose as the carbon source. Strains MA1 and MA0 produced 2.50 ± 0.21 and 1.49 ± 0.03 g L⁻¹ MA, respectively, while MA production was 1.68 times higher in MA1 than MA0 (Fig. 6C). In the strain MA1, MA yield from glucose was 0.15 mol mol⁻¹. Previously, we succeeded at producing high-yield MA (0.28 mol mol⁻¹) using metabolically engineered *E. coli* expressing fused enzymes (Fujiwara et al., 2018). These findings reveal that a combination of periplasmic G6P-capturing protein technique and existing technology has the potential of increasing MA yield beyond Tyr production.

Together, the results of the Tyr and MA production experiments indicate that the periplasmic expression of G6P-capturing proteins can increase the production of metabolites derived from chorismate, i.e., the end product of the shikimate pathway, and from shikimate pathway intermediates.

Phe production using a 1-L jar fermenter

Batch cultures of E Δ HI0 and BP Δ HI1 were performed using a 1-L jar fermenter. The modified M9 medium with 50 g L⁻¹ of glucose was used. Figure 7 shows the E Δ HI0 and BP Δ HI1 culture profiles in the jar fermenter. BP Δ HI1 produced 6.32 g L⁻¹ of Phe after 48 h of cultivation, which is 1.46 times higher than that produced by E Δ HI0 (4.34 g L⁻¹). In the BP Δ HI1 strain, the Phe yield from glucose was 0.13 mol mol⁻¹, which is 1.41 times higher than that in E Δ HI1, although it decreased compared to the test tube culture of the BP Δ HI1 strain (0.24 mol mol⁻¹). This result indicates that periplasmic GCP localization leads to enhancement of the shikimate pathway even in the case of jar fermenter cultivation. The Phe production yield in BP Δ HI1 was lower than the highest Phe production yield reported to date (0.26 mol mol⁻¹ in a fed-batch culture, 0.23 mol mol⁻¹ in batch culture) (Zhou et al., 2010). Zhou et al. used the L-tyrosine auxotrophic strain *E. coli* WSH-Z06, which is a laboratory strain of unknown genetic background, for Phe production. Since the L-tyrosine and L-tryptophan auxotrophic strains were used for Phe production in the present study, our strategy is likely applicable to the other strains that produced high yield shikimate pathway derivatives reported in previous studies.

Discussion

We demonstrated that localization of G6P-capturing proteins, including BGL, in the periplasm of *E. coli* accelerates the shikimate pathway. Positive effects of this BGL periplasmic localization on Phe production were also observed in strains metabolically engineered using a traditional approach. Other proteins with affinity for G6P similarly exerted a positive effect on Phe production when they localized to the periplasm. This phenomenon further resulted in the production of other shikimate pathway derivatives, i.e., Tyr and MA.

To reveal the underlying mechanisms, we identified key factors involved in this phenomenon: the G6P-capturing protein, G6P, and EIIC^{Glc} domain. Acceleration of the shikimate pathway was prevented with the absence of any one of these key factors. We confirmed the interaction between BGL and G6P by investigating enzymatic activity and SPR, as well as G6P secretion via the EIIC^{Glc} domain by measuring *uhpT* expression. Based on the results, we propose that the EIIC^{Glc} domain functions as a G6P transporter secreting G6P into the periplasm, while G6P dynamically binds to and detaches from G6P-capturing proteins in the periplasm. As intracellular PEP was increased by the periplasmic BGL localization, it was suggested that the accumulation of intracellular PEP accelerates the shikimate pathway. However, the mechanisms by which the proposed model causes intracellular PEP accumulation remain unclear.

Suppression of the PTS system has been used in many studies as a metabolic engineering approach to strengthen the shikimate pathway (Nakagawa et al., 2011; Noda and Kondo,

2017). The first step of the PTS system, the transfer of phosphate groups from PEP to EI, is a major PEP consumption reaction that contributes to reducing carbon flux in the shikimate pathway. A recent study reported a reverse reaction producing PEP from pyruvate when a phosphate group was received from phosphorylated EI (Long et al., 2017). Hence, the PTS system is deeply involved in regulating the balance between PEP and pyruvate, two metabolic branch points. In the present study, the strain disrupting *ptsHI*, encoding EI, had a positive effect on Phe production through periplasmic BGL localization. This result implies that an acceleration of the shikimate pathway by the periplasmic BGL localization is not due to PEP consumption suppression in the PTS system. In addition, the intracellular PEP concentration was increased by periplasmic BGL localization in the *ptsHI*-deficient strain, which indicates that the intracellular PEP accumulation results from a mechanism other than suppressing PEP consumption by the PTS system.

To transduce environmental information into appropriate cellular responses, the two-component system (TCS) is widely used in organisms that include *E. coli* (Jacob-Dubuisson et al., 2018). The TCS system comprises a sensor histidine kinase (SHK) and a cognate cytoplasmic response regulator (Jacob-Dubuisson et al., 2018). The SHK sensor domain is exposed to the periplasm and senses signals such as chemicals. When the SHK sensor domain senses signals, the response regulator takes a phosphorylated form through several steps. The phosphorylated response regulators can control the cellular condition, such as metabolism, by functioning as DNA-binding transcription factors. They can also display RNA-binding, protein-binding, or even enzymatic

activities (Jacob-Dubuisson et al., 2018). The Uhp system is a TCS that induces *uhpT* expression, encoding the hexose-6-phosphate:phosphate antiporter, by its periplasmic G6P (Västermark and Saier, 2014; Verhamme et al., 2002, 2001). In the present study, when using G6P as a carbon source instead of glucose, Phe production did not increase in the strain without G6P-capture proteins localization to the periplasm. This result suggested that increasing periplasmic G6P concentration is only insufficient to accelerate the shikimate pathway. In other words, the acceleration of the shikimate pathway does not result from the periplasmic G6P concentration by TCSs, including the Uhp system. In the G6P containing medium, periplasmic BGL localization increased Phe production in the strain where *ptsG* remained intact, which did not occur in a *ptsG*-deficient strain. This result suggested that G6P secretion from the cytoplasm into the periplasm via the EIIC^{Glc} domain is essential for accelerating the shikimate pathway, even in the presence of high levels of periplasmic G6P. The ratio of cytoplasmic G6P concentration or G6P concentration between the periplasm and cytoplasm might contribute to this phenomenon.

The regulatory mechanisms of the cytoplasmic metabolism have been well studied and various applied techniques for bioproduction have been developed (Nielsen and Keasling, 2016). However, the mechanisms regulating the periplasmic environment remain largely unknown. Changes in the periplasmic environment, including those in the periplasmic G6P levels, can affect overall metabolism. In the present study, periplasmic GCP expression results in an increased intracellular G6P concentration (Fig. 3B and S5C). Fig. 4D shows that the *uhpT* expression level in BP1 was significantly higher than that in E0,

indicating that the periplasmic concentration of free G6P was increased due to periplasmic BGL expression. We demonstrated that the periplasmic localization of intact/inactivated BGL or the three kinds of GCPs increased the Phe production (Figs. 1 and 5). Further, we confirmed that when a protein with no G6P affinity (GFP) was localized in the periplasm, no positive effect was observed on the Phe production. Even when the periplasmic concentration of free G6P is the same, the total G6P concentration in the periplasm (including free G6P and GCP–G6P complex) is higher when GCP is present in the periplasm (Supplementary Discussion 1). However, when the dissociation constant between GCP and G6P (K_d) is comparable to the apparent inhibition constant (K_i , Fig. 3D), the contribution of G6P-GCP affinity to the increasing G6P concentration would be limited. These results suggest that the periplasmic expression of GCP activates unknown mechanisms that increase the amount of G6P secreted in the periplasm and/or decrease the amount of G6P reuptake in the cytoplasm.

A hypothesis that explains the phenomenon identified in this study is that changes in the periplasmic environment resulted in a change in the intracellular G6P level and its balance between the cytoplasm and periplasm, affecting the overall metabolism, resulting in PEP accumulation and the acceleration of the shikimate pathway. Further elucidation of the mechanism requires individual G6P concentration measurement both in the periplasm and the cytoplasm, but it is technically difficult at present, partially because it is difficult to separate the small molecules present in the periplasm from the whole cell components and their concentrations cannot be measured accurately.

Conclusions

Here, we successfully discovered a new phenomenon that is beneficial for bioproduction and identified three key factors involved in this phenomenon—the G6P-capturing protein, G6P, and EIIC^{Glc} domain. Modification of the periplasmic environment via the expression of proteins having affinity for G6P is an original approach to increase target metabolite yield in bioproduction.

Acknowledgments

This work was supported by the JST-Mirai Program (Grant Number JPMJMI17EI), Japan (to S.N. and T.T.). Additionally, it was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (B) (Grant Number 19H02526), Japan (to T.T.). R.F. received support from Research Fellowship for Young Scientists from JSPS. This work was supported by the RIKEN Center for Sustainable Resource Science, Special Postdoctoral Researcher Program (to S.N.). The authors would like to thank Enago (www.enago.jp) for the English language review.

Author contributions

Conceptualization, R.F., T. S., S.N., and T.T.; Methodology, R.F., T. S., S.N., and T.T.; Formal Analysis, R.F., T. S., S.N., and T.T.; Writing–Original Draft, R.F.; Writing–Review & Editing, S.N., and T.T.; Investigation, R.F., M.N., Y.H., C.O., D.N., S.N., T.T., S. K., H. N., and M. U.; Supervision, A.K.

Declaration of competing interest

Kobe University has filed a patent application related to this technology on behalf of R.F., S.N., and T.T. The patent application number is JP 2019-123262. Other authors declare no competing interests.

Figures




Fig. 1. BGL expression in the *E. coli* periplasm increases Phe production. (A) Phe production after 48 h cultivation in E0, BD1, BP1, and BC1. (B) Immunoblotting of BC1, BD1, and BP1. Leftmost lanes: protein marker. (C) Phe production after 48 h cultivation in E0L, BD1L, E0M, BD1M, E0, and BD1. (D) Immunoblotting of BD1L, BD1M and BD1 (whole-cell extracts). Leftmost lane: protein marker. Data are presented as the average of three independent experiments, and error bars indicate standard error. *P* values were determined using two-tailed Student's *t*-tests (NS, *P* > 0.05; **P* < 0.05; ***P* < 0.01). NS: non-significant.




Fig. 2. Periplasmic BGL localization does not affect Phe production in EIIC^{Glc} domain-deficient strains. (A) Glucose transport by the PTS and GalP/Glk system. The lower table indicates disrupted, edited, and overexpressed genes in each strain. “Δ,” “X” and “+” indicate gene disruption, inactivating mutation and overexpression, respectively. (B) Phe production after 48 h cultivation. Light- and dark-blue bars indicate the production titers in EΔHI0 (control strain) and BGL-expressing strains (BDΔHI1 and BPΔHI1), respectively. (C) Phe production after 48 h cultivation in EΔHIC0, BPΔHIC1, EΔHIG0 and BPΔHIG1. (D) Phe production after 48 h cultivation in EΔG0, BPΔG1, EC⁴²¹S0 and BPC⁴²¹S1. (E) Phe production after 48 h cultivation in EdGB0, BPdGB1, EdGC0, and BPdGC1. Data are presented as the average of three independent experiments, and error bars indicate standard error. *P* values were determined using two-tailed Student’s *t*-tests (NS, *P* > 0.05; **P* < 0.05; ***P* < 0.01). NS: non-significant.




Fig. 3. G6P—a key metabolite, as demonstrated via metabolome analysis. (A)

Metabolism of glucose. (B) Intracellular concentrations of glycolysis and PPP

metabolites in BPAHI1 compared to EΔHI0 (control strain). (C) Diagram of the

hypothesized mechanism described in the text. (D) *In vitro* examination of BGL activity

inhibition by glucose and G6P. Blue circle and red diamond symbols indicate fractional

805 enzymatic activity with the addition of glucose and G6P, respectively. (E) SPR
806 sensorgrams for β -glucosidase against glucose and G6P. For SPR measurements, the flow
807 rate was $30 \mu\text{L min}^{-1}$, the immobilized amount of β -glucosidase was 8000 RU and the
808 analyte concentrations (glucose or G6P) were 391–200 mM. Data are presented as the
809 average of three independent experiments, and error bars indicate standard error. *P* values
810 were determined using two-tailed Student's *t*-tests (NS, $P > 0.05$; $*P < 0.05$; $**P < 0.01$).
811 NS: non-significant.




Fig. 4. G6P secretion and accumulation in the periplasm. (A) Diagram of the Uhp system. (B) Relative expression levels of *uhpT* in ATCC 31882 incubated in G6P-supplemented medium. ATCC 31882 was precultured overnight, then washed with LB medium. Subsequently, ATCC31882 was inoculated into LB medium supplemented with each G6P concentration at the initial OD₆₀₀ = 1.0, shaken at 37°C and 1000 rpm for 1 h with Maximizer MBR-022UP (TAITEC, Saitama, Japan), then sampled. (C) Relative *uhpT* expression levels in E0, E Δ G0 and E^{C421S0} cultured in a glucose-containing medium. (D) Relative *uhpT* expression levels in E0 and BP1 cultured in a glucose-containing medium. (E) Relative *uhpT* expression levels in E Δ G0 and BP Δ G1 cultured in a glucose-containing medium. “ Δ ” indicates gene disruption. “+” indicates overexpression. (F) Relative intracellular G6P concentration (magenta bars) and relative

824 *uhpT* expression levels (cyan bars) in P2GsE, P2GsC and P2GsC Δ *pgi* cultured in a
825 glucose-containing medium. (G) Relative *uhpT* expression levels in E Δ H10 and BP Δ H11
826 cultured in a glucose-containing medium. Data are presented as the mean of three
827 independent experiments, and the error bars indicate the standard error. *P* values were
828 determined using two-tailed Student's t-tests (NS, $P > 0.05$; * $P < 0.05$; ** $P < 0.01$). NS:
829 non-significant.




Fig. 5. Application of other proteins using the proposed mechanism. (A)

Hypothesized mechanism of G6P transport from the cytoplasm to the periplasm by the EIIC^{Glc} domain and G6P sequestration by the G6P-capturing protein (GCP). (B) Phe production in the periplasmic enzyme-expressing strains after 48 h cultivation. Data are presented as the average of three independent experiments, and the error bars indicate the standard error. *P* values were determined using two-tailed Student's *t*-tests (NS, $P > 0.05$; $*P < 0.05$; $**P < 0.01$). NS: non-significant.




Fig. 6. Production of other metabolites using G6P-capturing proteins. (A) Diagram

of the metabolic pathways that synthesize Tyr and MA. (B) Tyr production after 48 h of

cultivation in TYR0 and TYR1. (C) MA production after 48 h of cultivation in MA0 and

MA1. Data are presented as the average of three independent experiments, and the error

bars indicate the standard error. *P* values were determined using two-tailed Student's *t*-

tests (*P* < 0.01).**




Fig. 7. EΔHI0 and BPAHI1 culture profiles in a jar fermenter. Red, black, and blue symbols indicate cell growth, glucose concentration, and Phe concentration, respectively. The EΔHI0 and BPAHI1 profiles are indicated with dash lines, open symbols, and solid lines, closed symbols, respectively.

References

- Bodelón, G., Palomino, C., Fernández, L.Á., 2013. Immunoglobulin domains in *Escherichia coli* and other enterobacteria: from pathogenesis to applications in antibody technologies. *FEMS Microbiol. Rev.* 37, 204–250.
<https://doi.org/10.1111/j.1574-6976.2012.00347.x>
- Cabell, L.A., Monahan, M.K., Anslyn, E. V., 1999. A competition assay for determining glucose-6-phosphate concentration with a *tris*-boronic acid receptor. *Tetrahedron Lett.* 40, 7753–7756. [https://doi.org/10.1016/S0040-4039\(99\)01651-2](https://doi.org/10.1016/S0040-4039(99)01651-2)
- Chir, J.L., Wan, C.F., Chou, C.H., Wu, A.T., 2011. Hydrolysis of cellulose in synergistic mixtures of β -glucosidase and endo/exocellulase Cel9A from *Thermobifida fusca*. *Biotechnol. Lett.* 33, 777–782. <https://doi.org/10.1007/s10529-010-0500-9>
- Choi, J.H., Lee, S.Y., 2004. Secretory and extracellular production of recombinant proteins using *Escherichia coli*. *Appl. Microbiol. Biotechnol.* 64, 625–635.
<https://doi.org/10.1007/s00253-004-1559-9>
- Chung, H., Yang, J.E., Ha, J.Y., Chae, T.U., Shin, J.H., Gustavsson, M., Lee, S.Y., 2015. Bio-based production of monomers and polymers by metabolically engineered microorganisms. *Curr. Opin. Biotechnol.* 36, 73–84.
<https://doi.org/10.1016/j.copbio.2015.07.003>
- Chung Nan Chang, Wun-Jing, K., Chen, E.Y., 1986. Nucleotide sequence of the alkaline phosphatase gene of *Escherichia coli*. *Gene* 44, 121–125.
[https://doi.org/10.1016/0378-1119\(86\)90050-8](https://doi.org/10.1016/0378-1119(86)90050-8)
- Fernández, L.A., 2004. Prokaryotic expression of antibodies and affibodies. *Curr. Opin. Biotechnol.* 15, 364–373. <https://doi.org/10.1016/J.COPBIO.2004.06.004>

872 Fujiwara, R., Noda, S., Tanaka, T., Kondo, A., 2020. Metabolic engineering of
 873 *Escherichia coli* for shikimate pathway derivative production from glucose–xylose
 874 co-substrate. Nat. Commun. 11, 1–12. <https://doi.org/10.1038/s41467-019-14024-1>
 875 Fujiwara, R., Noda, S., Tanaka, T., Kondo, A., 2018. Muconic acid production using
 876 gene-level fusion proteins in *Escherichia coli*. ACS Synth. Biol. 7, 2698–2705.
 877 <https://doi.org/10.1021/acssynbio.8b00380>
 878 Georgiou, G., Segatori, L., 2005. Preparative expression of secreted proteins in bacteria:
 879 status report and future prospects. Curr. Opin. Biotechnol. 16, 538–545.
 880 <https://doi.org/10.1016/j.copbio.2005.07.008>
 881 Gonzalez-Perez, D., Ratcliffe, J., Tan, S.K., Wong, M.C.M., Yee, Y.P., Nyabadza, N.,
 882 Xu, J.-H., Wong, T.S., Tee, K.L., 2021. Random and combinatorial mutagenesis for
 883 improved total production of secretory target protein in *Escherichia coli*. Sci. Rep.
 884 11, 5290. <https://doi.org/10.1038/s41598-021-84859-6>
 885 Heng, S.S.J., Chan, O.Y.W., Keng, B.M.H., Ling, M.H.T., 2011. Glucan biosynthesis
 886 protein G is a suitable reference gene in *Escherichia coli* K-12. ISRN Microbiol.
 887 2011, 469053. <https://doi.org/10.5402/2011/469053>
 888 Hernández-Montalvo, V., Martínez, A., Hernández-Chavez, G., Bolivar, F., Valle, F.,
 889 Gosset, G., 2003. Expression of *galP* and *glk* in a *Escherichia coli* PTS mutant
 890 restores glucose transport and increases glycolytic flux to fermentation products.
 891 Biotechnol. Bioeng. 83, 687–694. <https://doi.org/10.1002/bit.10702>
 892 Ikeda, N., Miyamoto, M., Adachi, N., Nakano, M., Tanaka, T., Kondo, A., 2013. Direct
 893 cadaverine production from cellobiose using β -glucosidase displaying *Escherichia*
 894 *coli*. AMB Express 3, 1–7. <https://doi.org/10.1186/2191-0855-3-67>

895 Jacob-Dubuisson, F., Mechaly, A., Betton, J.-M., Antoine, R., 2018. Structural insights
 896 into the signalling mechanisms of two-component systems. *Nat. Rev. Microbiol.*
 897 2018 1610 16, 585–593. <https://doi.org/10.1038/s41579-018-0055-7>
 898 Jiang, Y., Chen, B., Duan, C., Sun, B., Yang, J., Yang, S., 2015. Multigene editing in the
 899 *Escherichia coli* genome via the CRISPR-Cas9 system. *Appl. Environ. Microbiol.*
 900 81, 2506–2514. <https://doi.org/10.1128/AEM.04023-14>
 901 Juminaga, D., Baidoo, E.E.K., Redding-Johanson, A.M., Batth, T.S., Burd, H.,
 902 Mukhopadhyay, A., Petzold, C.J., Keasling, J.D., 2012. Modular engineering of L-
 903 tyrosine production in *Escherichia coli*. *Appl. Environ. Microbiol.* 78, 89–98.
 904 <https://doi.org/10.1128/AEM.06017-11>
 905 Kurumbang, N.P., Vera, J.M., Hebert, A.S., Coon, J.J., Landick, R., 2020. Heterologous
 906 expression of a glycosyl hydrolase and cellular reprogramming enable *Zymomonas*
 907 *mobilis* growth on cellobiose. *PLoS One* 15, e0226235.
 908 <https://doi.org/10.1371/journal.pone.0226235>
 909 Lian, J., McKenna, R., Rover, M.R., Nielsen, D.R., Wen, Z., Jarboe, L.R., 2016.
 910 Production of biorenewable styrene: utilization of biomass-derived sugars and
 911 insights into toxicity. *J. Ind. Microbiol. Biotechnol.* 43, 595–604.
 912 <https://doi.org/10.1007/s10295-016-1734-x>
 913 Long, C.P., Au, J., Sandoval, N.R., Gebreselassie, N.A., Antoniewicz, M.R., 2017.
 914 Enzyme I facilitates reverse flux from pyruvate to phosphoenolpyruvate in
 915 *Escherichia coli*. *Nat. Commun.* 8, 14316. <https://doi.org/10.1038/ncomms14316>

916 Lütke-Eversloh, T., Stephanopoulos, G., 2007. L-Tyrosine production by deregulated
 917 strains of *Escherichia coli*. Appl. Microbiol. Biotechnol. 75, 103–110.
 918 <https://doi.org/10.1007/s00253-006-0792-9>
 919 Malherbe, G., Humphreys, D.P., Davé, E., 2019. A robust fractionation method for
 920 protein subcellular localization studies in *Escherichia coli*. Biotechniques 66, 171–
 921 178. <https://doi.org/10.2144/btn-2018-0135>
 922 Mirzadeh, K., Shilling, P.J., Elfageih, R., Cumming, A.J., Cui, H.L., Rennig, M.,
 923 Nørholm, M.H.H., Daley, D.O., 2020. Increased production of periplasmic proteins
 924 in *Escherichia coli* by directed evolution of the translation initiation region. Microb.
 925 Cell Fact. 19, 85. <https://doi.org/10.1186/s12934-020-01339-8>
 926 Morrison, J.F., 1969. Kinetics of the reversible inhibition of enzyme-catalysed reactions
 927 by tight-binding inhibitors. Biochim. Biophys. Acta - Enzymol. 185, 269–286.
 928 [https://doi.org/10.1016/0005-2744\(69\)90420-3](https://doi.org/10.1016/0005-2744(69)90420-3)
 929 Nakagawa, A., Minami, H., Kim, J.-S., Koyanagi, T., Katayama, T., Sato, F., Kumagai,
 930 H., 2011. A bacterial platform for fermentative production of plant alkaloids. Nat.
 931 Commun. 2, 326. <https://doi.org/10.1038/ncomms1327>
 932 Nielsen, J., Keasling, J.D., 2016. Engineering Cellular Metabolism. Cell 164, 1185–1197.
 933 <https://doi.org/10.1016/J.CELL.2016.02.004>
 934 Niu, H., Li, R., Liang, Q., Qi, Q., Li, Q., Gu, P., 2019. Metabolic engineering for
 935 improving L⁻ tryptophan production in *Escherichia coli*. J. Ind. Microbiol.
 936 Biotechnol. 46, 55–65. <https://doi.org/10.1007/s10295-018-2106-5>

937 Noda, S., Kondo, A., 2017. Recent advances in microbial production of aromatic
 938 chemicals and derivatives. Trends Biotechnol. 35, 785–796.
 939 <https://doi.org/10.1016/j.tibtech.2017.05.006>

940 Noda, S., Shirai, T., Oyama, S., Kondo, A., 2016. Metabolic design of a platform
 941 *Escherichia coli* strain producing various chorismate derivatives. Metab. Eng. 33,
 942 119–129. <https://doi.org/10.1016/j.ymben.2015.11.007>

943 Nonaka, D., Fujiwara, R., Hirata, Y., Tanaka, T., Kondo, A., 2021. Metabolic
 944 engineering of 1,2-propanediol production from cellobiose using beta-glucosidase-
 945 expressing *E. coli*. Bioresour. Technol. 329, 124858.
 946 <https://doi.org/10.1016/j.biortech.2021.124858>

947 Olson, M.M., Templeton, L.J., Suh, W., Youderian, P., Sariaslani, F.S., Gatenby, A.A.,
 948 Van Dyk, T.K., 2007. Production of tyrosine from sucrose or glucose achieved by
 949 rapid genetic changes to phenylalanine-producing *Escherichia coli* strains. Appl.
 950 Microbiol. Biotechnol. 74, 1031–1040. <https://doi.org/10.1007/s00253-006-0746-2>

951 Poddar, A., Azam, M.S., Kayikcioglu, T., Bobrovskyy, M., Zhang, J., Ma, X.,
 952 Labhsetwar, P., Fei, J., Singh, D., Luthey-Schulten, Z., Vanderpool, C.K., Ha, T.,
 953 2021. Effects of individual base-pairs on in vivo target search and destruction
 954 kinetics of bacterial small RNA. Nat. Commun. 12, 1–15.
 955 <https://doi.org/10.1038/s41467-021-21144-0>

956 Rodriguez, A., Martínez, J. a, Báez-Viveros, J.L., Flores, N., Hernández-Chávez, G.,
 957 Ramírez, O.T., Gosset, G., Bolivar, F., 2013. Constitutive expression of selected
 958 genes from the pentose phosphate and aromatic pathways increases the shikimic

959 acid yield in high-glucose batch cultures of an *Escherichia coli* strain lacking PTS
 960 and *pykF*. Microb. Cell Fact. 12, 86. <https://doi.org/10.1186/1475-2859-12-86>
 961 Satowa, D., Fujiwara, R., Uchio, S., Nakano, M., Otomo, C., Hirata, Y., Matsumoto, T.,
 962 Noda, S., Tanaka, T., Kondo, A., 2020. Metabolic engineering of *E. coli* for
 963 improving mevalonate production to promote NADPH regeneration and enhance
 964 acetyl- CoA supply. Biotechnol. Bioeng. 117, 2153–2164.
 965 <https://doi.org/10.1002/bit.27350>
 966 Schmidt T., 2019. Encyclopedia of Microbiology, 4th Editio. ed. Academic Press,
 967 Amsterdam.
 968 Shen, X., Wang, Jia, Wang, Jian, Chen, Z., Yuan, Q., Yan, Y., 2017. High-level De novo
 969 biosynthesis of arbutin in engineered *Escherichia coli*. Metab. Eng. 42, 52–58.
 970 <https://doi.org/10.1016/j.ymben.2017.06.001>
 971 Shirai, T., Matsuda, F., Okamoto, M., Kondo, A., 2013. Evaluation of control
 972 mechanisms for *Saccharomyces cerevisiae* central metabolic reactions using
 973 metabolome data of eight single-gene deletion mutants. Appl. Microbiol.
 974 Biotechnol. 97, 3569–3577. <https://doi.org/10.1007/s00253-012-4597-8>
 975 Sochacki, K.A., Shkel, I.A., Record, M.T., Weisshaar, J.C., 2011. Protein diffusion in the
 976 periplasm of *E. coli* under osmotic stress. Biophys. J. 100, 22–31.
 977 <https://doi.org/10.1016/j.bpj.2010.11.044>
 978 Soma, Y., Inokuma, K., Tanaka, T., Ogino, C., Kondo, A., Okamoto, M., Hanai, T.,
 979 2012. Direct isopropanol production from cellobiose by engineered *Escherichia coli*
 980 using a synthetic pathway and a cell surface display system. J. Biosci. Bioeng. 114,
 981 80–85. <https://doi.org/10.1016/j.jbiosc.2012.02.019>

982 Spiridonov, N.A., Wilson, D.B., 2001. Cloning and biochemical characterization of
 983 BglC, a β -glucosidase from the cellulolytic actinomycete *Thermobifida fusca*. Curr.
 984 Microbiol. 42, 295–301. <https://doi.org/10.1007/s002840110220>
 985 Stock, J.B., Rauch, B., Roseman, S., 1977. Periplasmic space in *Salmonella typhimurium*
 986 and *Escherichia coli*. J. Biol. Chem. 252, 7850–7861.
 987 [https://doi.org/10.1016/S0021-9258\(17\)41044-1](https://doi.org/10.1016/S0021-9258(17)41044-1)
 988 Sun, J., Lin, Y., Shen, X., Jain, R., Sun, X., Yuan, Q., Yan, Y., 2016. Aerobic
 989 biosynthesis of hydrocinnamic acids in *Escherichia coli* with a strictly oxygen-
 990 sensitive enoate reductase. Metab. Eng. 35, 75–82.
 991 <https://doi.org/10.1016/j.ymben.2016.02.002>
 992 Tanaka, T., Kawabata, H., Ogino, C., Kondo, A., 2011. Creation of a
 993 cellooligosaccharide-assimilating *Escherichia coli* strain by displaying active beta-
 994 glucosidase on the cell surface via a novel anchor protein. Appl. Environ. Microbiol.
 995 77, 6265–70. <https://doi.org/10.1128/AEM.00459-11>
 996 Thompson, B., Pugh, S., Machas, M., Nielsen, D.R., 2018. Muconic acid production via
 997 alternative pathways and a synthetic “Metabolic Funnel.” ACS Synth. Biol. 7, 565–
 998 575. <https://doi.org/10.1021/acssynbio.7b00331>
 999 Västermark, A., Saier, M.H., 2014. The involvement of transport proteins in
 1000 transcriptional and metabolic regulation. Curr. Opin. Microbiol. 18, 8–15.
 1001 <https://doi.org/10.1016/j.mib.2014.01.002>
 1002 Verhamme, D.T., Arents, J.C., Postma, P.W., Crielaard, W., Hellingwerf, K.J., 2001.
 1003 Glucose-6-phosphate-dependent phosphoryl flow through the Uhp two-component

1004 regulatory system. Microbiology 147, 3345–3352.

1005 <https://doi.org/10.1099/00221287-147-12-3345>

1006 Verhamme, D.T., Postma, P.W., Crielaard, W., Hellingwerf, K.J., 2002. Cooperativity in

1007 signal transfer through the Uhp system of *Escherichia coli*. J. Bacteriol. 184, 4205–

1008 4210. <https://doi.org/10.1128/JB.184.15.4205-4210.2002>

1009 Wu, W., Guo, X., Zhang, M., Huang, Q., Qi, F., Huang, J., 2018. Enhancement of L-

1010 phenylalanine production in *Escherichia coli* by heterologous expression of

1011 Vitreoscilla hemoglobin. Biotechnol. Appl. Biochem. 65, 476–483.

1012 <https://doi.org/10.1002/bab.1605>

1013 Zhang, H., Pereira, B., Li, Z., Stephanopoulos, G., 2015. Engineering *Escherichia coli*

1014 coculture systems for the production of biochemical products. Proc. Natl. Acad. Sci.

1015 112, 8266–8271. <https://doi.org/10.1073/pnas.1506781112>

1016 Zheng, H., Taraska, J., Merz, A.J., Gonen, T., 2010. The prototypical H⁺/galactose

1017 symporter GalP assembles into functional trimers. J. Mol. Biol. 396, 593–601.

1018 <https://doi.org/10.1016/j.jmb.2009.12.010>

1019 Zhou, H., Liao, X., Wang, T., Du, G., Chen, J., 2010. Enhanced l-phenylalanine

1020 biosynthesis by co-expression of *pheA*^{fbr} and *aroF*^{wt}. Bioresour. Technol. 101, 4151–

1021 4156. <https://doi.org/10.1016/j.biortech.2010.01.043>

1022

Supplementary materials

This file includes:

Figures S1 to S5

Supplementary discussion 1

Tables S1 to S3

SI References




Fig. S1. Effect of BGL expression level or enzymatic activity on Phe production. (A)

Bacterial cell growth in glucose medium. Blue bars indicate the OD₆₀₀ of the control strain (E0) and strains expressing Blc-Tfu0937, PelB-Tfu0937, and Tfu0937 (BD1, BP1, and BC1, respectively). (B) Whole-cell activity of BGL in E0, BD1, BP1 and BC1. (C) Whole-cell activity of BGL in E0, BD1L, BD1M, BD1 and BD2. (D) L-phenylalanine production after 48 h cultivation in E0 and a strain expressing inactivated BGL (BD2). n.d., not detected. Data are presented as the average of three independent experiments, and error bars indicate standard error. *P* values were determined using two-tailed Student's *t*-tests (NS, *P* > 0.05; ***P* < 0.01). BGL, β -glucosidase; NS, non-significant.




Fig. S2. Intracellular PEP, pyruvate, and acetyl-CoA concentrations. Intracellular PEP, pyruvate, and acetyl-CoA concentrations in BDΔHI1 relative to EΔHI0 (A), BPΔHI1 relative to EΔHI0 (B), BPΔHIG1 relative to EΔHIG0 (C) and BPΔG1 relative to EΔG0 (D). Data are presented as the mean of three independent experiments, and error bars indicate standard error. *P* values were determined using two-tailed Student's *t*-tests (NS, *P* > 0.05; **P* < 0.05; ***P* < 0.01). NS, non-significant; PEP, phosphoenolpyruvate.




Fig. S3. Metabolome analysis of glycolysis and the PPP in strains with periplasmic BGL localization. (A) Intracellular G6P concentrations in BPΔHIG1 relative to EΔHIG0 (control strain). (B) Catabolic pathway for glucose, xylose and fructose. (C) Phe production after 48 h cultivation in BPΔHI1 and EΔHI0 using xylose or fructose as a carbon source. (D) Intracellular G6P concentrations with xylose as the substrate in BPΔHI1 relative to EΔHI0. (E) Intracellular G6P concentrations with fructose as the substrate in BPΔHI1 relative to EΔHI0. Data are presented as the mean of three independent experiments, and error bars indicate standard errors. *P* values were determined using two-tailed Student's *t*-tests (NS, *P* > 0.05; **P* < 0.05; ***P* < 0.01). BGL, β-glucosidase; G6P, glucose-6-phosphate; NS, non-significant; PPP, pentose phosphate pathway.




Fig. S4. Phe production in G6P-containing medium. Analysis of *uhpT* expression. (A) Phe production in strain E0 cultured in media containing 55.5 mM glucose or G6P. (B) Bacterial cell growth of E0 cultured in media containing 55.5 mM glucose or G6P. (C) L-phenylalanine production in E0 and BP1 cultured in media containing 55.5 mM G6P. (D) L-phenylalanine production in EΔG0 and BPΔG1 cultured in media containing 55.5 mM G6P. Data are presented as the mean of three independent experiments, and error bars indicate standard error. *P* values were computed using two-tailed Student's *t*-test (NS, *P* > 0.05; **, *P* < 0.01). G6P, glucose-6-phosphate.




Fig. S5. Analysis of the application of G6P-capturing proteins. (A) L-phenylalanine production after 48 h cultivation in Pgi and Zwf overexpression strains. Light- and dark-green bars indicate L-phenylalanine production by E0 (control strain) and strains expressing native Pgi and Zwf in the cytoplasm (PC1 and ZC1), respectively. (B) Western blotting of Zwf. As indicated in the figure, the left four lanes correspond to a molecular weight protein marker and whole-cell extract samples (ZC1, ZP1, and ZP2). The right four lanes correspond to a protein marker and periplasmic extract samples (ZC1, ZP1, and ZP2). Zwf expression levels in the periplasmic extracts of strains ZP1 and ZP2 were 6.1- and 5.8-times higher than those in ZC1. An ANTI-FLAG M2 monoclonal antibody (Sigma-Aldrich) and an anti-rabbit IgG (Fc) AP conjugate (Promega Corp.) were used to detect Zwf and PelB-Zwf fused with a FLAG-tag. (C) Intracellular G6P concentrations in strains expressing G6P-capturing proteins in the periplasm relative to E0 (control strain). Data are presented as the mean of three

independent experiments, and error bars indicate standard error. *P* values were computed using two-tailed Student's *t*-test (NS, $P > 0.05$; $*P < 0.05$). G6P, glucose-6-phosphate.

Supplementary discussion 1

The assumed reaction mechanism, in which one GCP molecule captures one G6P molecule to form a GCP-G6P complex, then dissociating to GCP and G6P, is shown in Eq. 2:



Assuming that this reaction has reached the equilibrium rapidly, the dissociation constant (K_d) is set as follows.

$$K_d = \frac{[\text{GCP}][\text{G6P}]}{[\text{GCP-G6P}]} \text{ (Eq. 3)}$$

Focusing on the periplasmic concentration of the GCP-G6P complex, converting Eq. 3 results in the following Eq. 4.

$$[\text{GCP-G6P}]_p = \frac{[\text{GCP}]_p [\text{G6P}]_p}{K_d} \text{ (Eq. 4)}$$

$[\text{GCP-G6P}]_p$, $[\text{GCP}]_p$, and $[\text{G6P}]_p$ indicate the periplasmic concentration of the GCP-G6P complex, free GCP, and free G6P, respectively. The total concentration of the periplasmic GCP ($[\text{GCP}]_{p0}$) is the sum of $[\text{GCP}]_p$ and $[\text{GCP-G6P}]_p$, Eq. 4 results in the following Eq. 5.

$$[\text{GCP-G6P}]_p = \frac{[\text{G6P}]_p [\text{GCP}]_{p0}}{[\text{G6P}]_p + K_d} \text{ (Eq. 5)}$$

The total concentration of the periplasmic G6P ($[\text{G6P}]_{p0}$) is the sum of $[\text{G6P}]_p$ and $[\text{GCP-G6P}]_p$, Eq. 5 results in the following Eq. 6.

$$[\text{G6P}]_{p0} = \left(1 + \frac{[\text{GCP}]_{p0}}{[\text{G6P}]_p + K_d} \right) \cdot [\text{G6P}]_p \text{ (Eq. 6)}$$

Eq.6 means that even if the periplasmic concentration of free G6P is the same, the total G6P concentration in the periplasm (including free G6P and GCP-G6P complex) is higher when GCP is present in the periplasm.

Table S1. Strains and plasmids used in this study

Strains	Genotype	Source or reference
ATCC31882	L-Phenylalanine-overproducing strain	ATCC
ATCC31882 Δ <i>ptsG</i>	ATCC31882 Δ <i>ptsG</i>	This study
CFT1	ATCC31882 <i>ptsHI::P_{AllacO-1} -glk-galP</i>	Noda et al., 2016
CFT1 Δ <i>crr</i>	ATCC31882 <i>ptsHI::P_{AllacO-1} -glk-galP</i> Δ <i>crr</i>	This study
CFT1 Δ <i>ptsG</i>	ATCC31882 <i>ptsHI::P_{AllacO-1} -glk-galP</i> Δ <i>ptsG</i>	This study
CFT1 Δ <i>pheA</i>	ATCC31882 <i>ptsHI::P_{AllacO-1} -glk-galP</i> Δ <i>pheA</i>	This study
C421S	ATCC31882 <i>ptsG::ptsG^{C421S}</i>	This study
P2Gs	ATCC31882 <i>ptsG::P_{AllacO-1} -glk-galP</i> Δ <i>sgrS</i>	This study
P2Gs Δ <i>pgi</i>	ATCC31882 <i>ptsG::P_{AllacO-1} -glk-galP</i> Δ <i>sgrS</i> Δ <i>pgi</i>	This study
TYR	ATCC31882 <i>trpE::tyrA^{fbr} ΔpheA</i>	This study
E0	ATCC31882 harboring pHLA	This study
BD1	ATCC31882 harboring pHLA-blc-Tfu0937	This study
E0L	ATCC31882 harboring pSAK	This study
BD1L	ATCC31882 harboring pSAK-blc-Tfu0937	This study
E0M	ATCC31882 harboring pZA23MCS	This study
BD1M	ATCC31882 harboring pZA23-blc-Tfu0937	This study
BD2	ATCC31882 harboring pHLA-blc-Tfu0937E ³⁸⁸ A	This study
BP1	ATCC31882 harboring pHLA-pelB-Tfu0937	This study
BC1	ATCC31882 harboring pHLA-Tfu0937	This study
E Δ HI0	CFT1 harboring pHLA	This study
BD Δ HI1	CFT1 harboring pHLA-blc-Tfu0937	This study
BP Δ HI1	CFT1 harboring pHLA-pelB-Tfu0937	This study
E Δ HIC0	CFT1 Δ <i>crr</i> harboring pHLA	This study
BP Δ HIC1	CFT1 Δ <i>crr</i> harboring pHLA-pelB-Tfu0937	This study
E Δ HIG0	CFT1 Δ <i>ptsG</i> harboring pHLA	This study
BP Δ HIG1	CFT1 Δ <i>ptsG</i> harboring pHLA-pelB-Tfu0937	This study
E Δ G0	ATCC31882 Δ <i>ptsG</i> harboring pHLA	This study
BP Δ G1	ATCC31882 Δ <i>ptsG</i> harboring pHLA-pelB-Tfu0937	This study
E ^{C421S} 0	C421S harboring pHLA	This study
BP ^{C421S} 1	C421S harboring pHLA-prlB-Tfu0937	This study

dGB	ATCC31882 Δ <i>ptsG</i> harboring pZA23-EIIB ^{Glc}	This study
dGC	ATCC31882 Δ <i>ptsG</i> harboring pZA23-EIIC ^{Glc}	This study
EdGB0	dGB harboring pHLA	This study
BPdGB1	dGB harboring pHLA pHLA-pelB-Tfu0937	This study
EdGC0	dGC harboring pHLA	This study
BPdGC1	dGC harboring pHLA pHLA-pelB-Tfu0937	This study
P2GsE	P2Gs harboring pZA23-MCS	This study
P2GsC	P2Gs harboring pZA23-EIIC ^{Glc}	This study
P2GsC Δ <i>pgi</i>	P2Gs Δ <i>pgi</i> harboring pZA23-EIIC ^{Glc}	This study
AP1	ATCC31882 harboring pHLA-pelB-phoA	This study
AP2	ATCC31882 harboring pHLA-pelB-phoAS ¹²⁴ A	This study
PP1	ATCC31882 harboring pHLA-pelB-pgi	This study
PP2	ATCC31882 harboring pHLA-pelB-pgiH ³⁸⁶ A	This study
PC1	ATCC31882 harboring pHLA-pgi	This study
ZP1	ATCC31882 harboring pHLA-pelB-zwf	This study
ZP2	ATCC31882 harboring pHLA-pelB-zwfH ²³⁹ A	This study
ZC1	ATCC31882 harboring pHLA-zwf	This study
GP1	ATCC31882 harboring pHLA-pelB-gfp	This study
TYR0	TYR harboring pHLA	This study
TYR1	TYR harboring pHLA-blc-Tfu0937	This study
MA0	CFT1 Δ <i>pheA</i> harboring pSAK-ZYc and pHLA	This study
MA1	CFT1 Δ <i>pheA</i> harboring pSAK-ZYc and pHLA-pelB-Tfu0937	This study
Plasmids		
pHLA	<i>P_{HCE}</i> , <i>ColE1 ori</i> , <i>Amp^r</i>	Tanaka et al., 2011
pHLA-blc-Tfu0937	pHLA expressing Blc-Tfu0937	This study
pHLA-blc-Tfu0937 ^{E388A}	pHLA expressing Blc-Tfu0937E ³⁸⁸ A	This study
pHLA-pelB-Tfu0937	pHLA expressing PelB-Tfu0937	This study
pHLA-Tfu0937	pHLA expressing Tfu0937	This study
pHLA-blc-Tfu0937-FLAG	pHLA expressing Blc-Tfu0937E ³⁸⁸ A fused with FLAG-tag	This study
pHLA-pelB-Tfu0937-FLAG	pHLA expressing PelB-Tfu0937 fused with FLAG-tag	This study
pHLA-Tfu0937-FLAG	pHLA expressing Tfu0937 fused with FLAG-tag	This study

pHLA-pelB-phoA	pHLA expressing PelB-PhoA	This study
pHLA-pelB-phoA ^{S124A}	pHLA expressing PelB-PhoA ^{S124A}	This study
pHLA-pelB-pgi	pHLA expressing PelB-Pgi	This study
pHLA-pelB-pgi ^{H386A}	pHLA expressing PelB-PgiH ^{386A}	This study
pHLA-pgi	pHLA expressing Pgi	This study
pHLA-pelB-zwf	pHLA expressing PelB-Zwf	This study
pHLA-pelB-zwf ^{H239A}	pHLA expressing PelB-ZwfH ^{239A}	This study
pHLA-zwf	pHLA expressing Zwf	This study
pHLA-pelB-zwf-FLAG	pHLA expressing PelB-Zwf fused with FLAG-tag	This study
pHLA-pelB-zwf ^{H239A} -FLAG	pHLA expressing PelB-ZwfH ^{239A} fused with FLAG-tag	This study
pHLA-zwf-FLAG	pHLA expressing Zwf fused with FLAG-tag	This study
pHLA-pelB-gfp	pHLA expressing PelB-GFP	This study
pSAK	<i>P_{AlacO1}</i> , <i>SC101 ori</i> , and <i>Cm^r</i>	Noda et al., 2017
pSAK-blc-Tfu0937	pSAK expressing Blc-Tfu0937	This study
pSAK-blc-Tfu0937-FLAG	pSAK expressing Blc-Tfu0937 fused with FLAG-tag	This study
pSAK-P _{trc}	<i>P_{trc}</i> , <i>SC101 ori</i> , and <i>Cm^r</i>	Fujiwara et al., 2020
pSAK-ZYc	pSAK-P _{trc} containing <i>aroZ</i> , <i>aroY</i> , and <i>cata</i>	Fujiwara et al., 2020
pSAK- <i>tyrA</i> ^{fbr}	pSAK-P _{trc} containing <i>tyrA</i> ^{fbr} and feedback-inhibition-resistant (fbr) derivatives of <i>tyrA</i>	Fujiwara et al., 2020
pZA23MCS	<i>P_{AllacO-1}</i> , <i>p15A ori</i> , <i>Km^r</i>	Expressys
pZA23-blc-Tfu0937	pZA23MCS expressing Blc-Tfu0937	This study
pZA23-blc-Tfu0937	pZA23MCS expressing Blc-Tfu0937 fused with FLAG-tag	This study
pZA23-EIIB ^{Glc}	pHLA expressing EIIB ^{Glc} domain	This study
pZA23-EIIC ^{Glc}	pHLA expressing EIIC ^{Glc} domain	This study
pTargetF	Constitutive expression of sgRNA	Addgene
pCas	Constitutive expression of cas9 and inducible expression of λ RED and sgR	Addgene
pT Δ ptsG	Constitutive expression of sgRNA with donor-editing template DNA for <i>ptsG</i> disruption	This study
pT Δ crr	Constitutive expression of sgRNA with donor-editing template DNA for <i>crr</i> disruption	This study
pT Δ pheA	Constitutive expression of sgRNA with donor-editing template DNA for <i>pheA</i> disruption	Fujiwara et al., 2020

pTΔsgrS	Constitutive expression of sgRNA with donor-editing template DNA for <i>sgrS</i> disruption	This study
pTΔpgi	Constitutive expression of sgRNA with donor-editing template DNA for <i>pgi</i> disruption	This study
pTtrpE::tyr ^{fbr}	Constitutive expression of sgRNA with donor-editing template DNA for <i>tyrA</i> ^{fbr} insertion in <i>trpE</i> locus	This study
pTptsG::galP-gluk	Constitutive expression of sgRNA with donor-editing template DNA for <i>galP-gluk</i> insertion in <i>ptsG</i> locus	This study

Table S2. Primers used in the present study

Plasmids	Primers	Sequences
pHLA-blc-tfu0937 ^{E388A}	E388A_for	CTACCCGGGCTGCCGCTGTACATCACCGCGAAC GGCGCCGCCTTCGAGGAC
	E388A_re	GTCCTCGAAGGCGGCGCCGTTTCGCGGTGATGTAC AGCGGCAGGCCCGGGTAG
pHLA-pelB-tfu0937	pelB_Tfu0937_f1	CCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAG CCGGCGATGGCCATGACCTCGCAATCGACGACTC C
	XhoI_Tfu0937_re	GCCAAGCTTCTCGAGCTATTCCTGTCCGAAGATT CCCCCG
	Bgl2_pelB_for	TGGAAAAAGGAGATCTGATGAAATACCTGCTGCC GACCGCTGCTGCTGGTCTGCTGC
pHLA-tfu0937	n.s._tfu0937_f	TGGAAAAAGGAGATCTGATGACCTCGCAATCGAC GACTCC
	n.s._tfu0937_r	GCCAAGCTTCTCGAGCTATTCCTGTCCGAAGATT CCCCCG
pHLA-phoA	phoA_f	TGGAAAAAGGAGATCTGATGAAACAAAGCACTA TTGCACTGGCACTCTTACCG
	phoA_r	AGCCAAGCTTCTCGAGTTATTTAGCCCCAGAGC GGCTTTC
pHLA-phoA ^{S124A}	phoA_S124A_f	GTTGCTGATGCGGCCGCGTCGGTGACGTAGTCCG GTTTGCCG
	phoA_S124A_r	CGTCACCGACGCGGCCGCATCAGCAACCGCCTGG TCAACCG
pHLA-pelB-pgi	pelB_pgi_f1	CCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAG CCGGCGATGGCCATGAAAAACATCAATCCAACGC AGACCG
	XhoI_pgi_re	GCCAAGCTTCTCGAGTTAACCGCGCCACGCTTTA TAGCGG
pHLA-pelB-pgi ^{H386A}	pgi_H386A_smaI_for	CAGACTGGCCCGATTATCTGGGGTGAACCCGGGA CTAACGGTCAGGCCGCGTTCTACCAGCTGATCCA CCAGGGAAC
	pgi_H386A_smaI_re	GTTCCCTGGTGGATCAGCTGGTAGAACGCGGCCT GACCGTTAGTCCCGGGTTCACCCCAGATAATCGG GCCAGTCTG
pHLA-pelB-zwf	pelB_zwf_f1	CCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAG CCGGCGATGGCCATGGCGGTAACGAAACAGCC CAG
	XhoI_zwf_re	GCCAAGCTTCTCGAGTTACTCAAACCTCATTCCAG GAACGACCATC

pHLA-pelB-zwf ^{H239A}	zwf_H239A_pstI_for	CGGTCAGATGCGCGACATGATCCAGAACGCCCTGCTGCAGATTCTTTGCATGATTGCGATGTCTCCGCC
	zwf_H239A_pstI_re	GGCGGAGACATCGCAATCATGCAAAGAATCTGCAGCAGGGCGTTCTGGATCATGTCGCGCATCTGACCG
pHLA-zwf	no-sig._zwf_Fw	GGAAAAAGGAGATCTGATGGCGGTAACGCAAACAGCCAG
	no-sig._zwf_Rv	GCCAAGCTTCTCGAGTTACTCAAATCATTCCAGGAACGACCAT
pHLA-pelB-gfp	gfp_f1	CCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGCGATGGCCATGGTGAGCAAGGGCGAGGAGCTG
	gfp_f2	TGGAAAAAGGAGATCTGATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGC
	gfp_r	GCCAAGCTTCTCGAGCTACTTGTACAGCTCGTCCATGCCGAGAGTGATC
pHLA-pgi	no-sig._pgi_Fw	GGAAAAAGGAGATCTGATGAAAAACATCAATCCAACGCAGACCG
	no-sig._pgi_Rv	GCCAAGCTTCTCGAGTTAACCGCGCCACGCTTTATAGCG
pSAK-blc-tfu0937	c.n._Tfu0937_f	TCGTCTTCACCTCGAGGCTCCAGATCGCTAGCTTGATCTCTCC
pZA23-blc-tfu0937	c.n._Tfu0937_r	ATTCGATATCAAGCTTCATTTATCAGGGTTATTGCTCATGAGCGGATAC
pZA23-EIIB ^{Glc}	pZ_EIIB_f	TTAAAGAGGAGAAAGGTACC ATGGCGACTGAAGATGCAAAAGCGACAG
	pZ_EIIB_r	ATTCGATATCAAGCTCTATTAGTGGTTACGGATGTACTCATCCATCTCGG
pZA23-EIIC ^{Glc}	pZ_EIIC_f	TTAAAGAGGAGAAAGGTACC ATGTTTAAGAATGCATTTGCTAACCTGCAAAAGG
	pZ_EIIC_r	ATTCGATATCAAGCTCTATTAGTCTTCACGACCCGCGTTTTTCAG
pTΔptsG	sgRNA ptsG Fw	GATTGGTTCTGCAATCCAGCTAGCATTATACCTAGGACTGAGCTAGCTGTCAAGG
	sgRNA ptsG Rv	GATTGCAGAACCAATCGGGGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGC
	HomSeq Up ptsG Fw	TGCTTTTTTTGAATTCGCTTAGATGCCCTGTACACGGCGAG
	HomSeq Up ptsG Rv	CTGTCTGGTGGCTTCCACCGGAGATAATCCCTCCGAGTACGC
	HomSeq Dw ptsG Fw	GAGGGATTATCTCCGGTGGAAGCCACCAGACAGTTTACCCGCAGTC

	HomSeq Dw ptsG Rv	GCTTCTGCAGGTCGACCTGATCCACTTTAGACAC ATCAGCAACGC
pT Δ crr	sgRNA crr Fw	GCTGGAAGAGAAAGCCAAGCTAGCATTATACCTA GGACTGAGCTAGCTGTCAAGG
	sgRNA crr Rv	GGCTTTCTCTTCCAGCAGGGTTTTAGAGCTAGAA ATAGCAAGTTAAAATAAGGC
	HomSeq Up crr Fw	TGCTTTTTTTGAATTCTTGCTGGCGATGAACGTGC TACACTTC
	HomSeq Up crr Rv	GATAACCGGGGTTTCACCCGGCACGTCTTCGATA TTGACGATCTC
	HomSeq Dw crr Fw	GAAGACGTGCCGGGTGAAACCCCGGTTATCCGCA TCAAGAAGT
	HomSeq Dw crr Rv	GCTTCTGCAGGTCGACGATCTCGACAGTGCCATT GCTGCCG
pT Δ pheA	sgRNA pheA Fw	CCATTGTTTGGTTCGTTTTAGAGCTAGAAAT AGCAAGTTAAAATAAGGCTAGTCCG
	sgRNA pheA Rv	ACCAACAAACAATGGTCACTCGTATTATACCTAG GACTGAGCTAGCTGTCAAGGATCCAG
	HomSeq Up pheA Fw	TGCTTTTTTTGAATTCTACCGTTTTCTTCGCATTC TTTTTTACCT
	HomSeq Up pheA Rv	TCAGACACGTTACTAGTGCCTGCTGAGTTAATAC GGAATCTTCAA
	HomSeq Dw pheA Fw	ACTCAGCAGGCACTAGTAACGTGTCTGATCAGGT TCCGGC
	HomSeq Dw pheA Rv	AATAGATCTAAGCTTATACGCACAGCGTTTTTCAG AGTGAA
pT Δ sgrS	sgRNA sgrS Fw	AGTCAACTTTCAGAATTGGTTTTAGAGCTAGAAA TAGCAAGTTAAAATAAGGCTAGTCCG
	sgRNA sgrS Rv	TTCTGAAAGTTGACTTGACTCGTATTATACCTAGG ACTGAGCTAGCTGTCAAGGATCCAG
	HomSeq Up sgrS Fw	TCGGTGCTTTTTTTGAATTCGTCTTCCGCCCGCTG TTGCT
	HomSeq Up sgrS Rv	GCGCGGCGAGACTAGTGACTTAATATAGGGAAA ATAAAATTGCTGTCTTTTGCACAG
	HomSeq Dw sgrS Fw	CCCTATATTAAGTCACTAGTCTCGCCGCGCTAAA AAGGGAACG
	HomSeq Dw sgrS Rv	AGGGTAATAGATCTAAGCTTAGCACACCACAGGT GATAAGCGTC
pT Δ pgi	sgRNA pgi Fw	CCCAGAACTCGAACATGTGTTTTAGAGCTAGAAA TAGCAAGTTAAAATAAGGCTAGTCCG
	sgRNA pgi Rv	TGTTTCGAGTTCTGGGACACTCGTATTATACCTAG GACTGAGCTAGCTGTCAAGGATCCAG

	HomSeq Up <i>pgi</i> Fw	TCGGTGCTTTTTTTGAATTCTCACTGAAGAGACGC TGGCGA
	HomSeq Up <i>pgi</i> Rv	AAGAAATTGTTACTAGTGCACCTCCGCGATGTGA GTCC
	HomSeq Dw <i>pgi</i> Fw	CGCGGAAGTGCACTAGTAACAATTTCTTTGGTGC GGAAACTGA
	HomSeq Dw <i>pgi</i> Rv	AGGGTAATAGATCTAAGCTTCGGCACCACGTAGT CAAGCG
pTrpE::tyr ^{fbr}	sgRNA <i>trpE</i> Fw	GCTGCCAGTGGTTTCCGTGCTAGCATTATACCTA GGACTGAGCTAGCTGTCAAGG
	sgRNA <i>trpE</i> Rv	GGAAACCACTGGCAGCGGGGTTTTAGAGCTAGA AATAGCAAGTTAAAATAAGGC
	HomSeq Up <i>trpE</i> Fw	TGCTTTTTTTGAATTCGCAATCAGATACCCAGCCC GCCTAATGAG
	HomSeq Up <i>trpE</i> Rv	GGGTGAAATCGCGGCCGCCACAAGGTCATAAGA GAACAGGCCGCCG
	HomSeq Dw <i>trpE</i> Fw	GACCTTGTGGCGGCCGCGATTTACCCCTATTTGG CGCGTCGC
	HomSeq Dw <i>trpE</i> Rv	GCTTCTGCAGGTCGACGTGGCGATACCGTTTTCC ACCAGC
	tyr _{ins} Fw	GGGTGAAATCGCGGCCGCCCCAGTCTTTCGACTG AGCCTTTTCG
	tyr _{ins} Rv	GACCTTGTGGCGGCCGCATAGGCGTATCACGAGG CCCTTTCGTC
pTptsG::galP -glk	pTptsG _{inv} .Fw	CCGCCCTAGACCTAGGGACTGCGGGTAAACTGTC TGGTGGCTTC
	pTptsG _{inv} .Rv	GCTCACAATTCTCGAGCACCGGAGATAATCCCTC CGAGTACGC
	galP-gl _k _{ins} Fw	CTCGAGAATTGTGAGCGGATAACAATTGACATTG TGAG
	galP-gl _k _{ins} Rv	CCTAGGTCTAGGGCGGCGGATTTGTC
Real-time PCR primers for <i>mdoG</i>	<i>mdoG</i> _Fw	TTGCACGACTCTAACGGTCT
	<i>mdoG</i> _Rv	TTCCATGGAGAAGCTGCTGA
Real-time PCR primers for <i>uhpT</i>	<i>uhpT</i> _Fw	TCTTTGCGTTGGGTTTCCTG
	<i>uhpT</i> _Rv	TGGCAAAGCTGTCACCAATC

Table S3. Plasmids construction

Products	Primers or Restriction enzymes	Template	Methods
fragment 1	E388A_for E388A_re	pHLA-blc-Tfu0937	PCR
pHLA-blc-Tfu0937 ^{E389A}	-	fragment 1	In-Fusion HD cloning kit
fragment 2	pelB_Tfu0937_f1 Bgl2_pelB_for	pHLA-blc-Tfu0937	PCR
fragment 3	Bgl2_pelB_for XhoI_Tfu0937_re	fragment 2	PCR
fragment 4	<i>Bgl</i> III <i>Xho</i> I	pHLA	Restriction enzyme digestion
pHLA-pelB-Tfu0937	- -	fragment 3 fragment 4	In-Fusion HD cloning kit
fragment 5	n.s._tfu0937_f n.s._tfu0937_r	pHLA-blc-Tfu0937	PCR
pHLA-Tfu0937	-	fragment 5 fragment 4	In-Fusion HD cloning kit
fragment 6	Tfu0937-FLAG_Fw Tfu0937-FLAG_Rv	pHLA-blc-Tfu0937	PCR
pHLA-blc-Tfu0937-FLAG	-	fragment 6	In-Fusion HD cloning kit
fragment 7	Tfu0937-FLAG_Fw Tfu0937-FLAG_Rv	pHLA-pelB-Tfu0937	PCR
pHLA-pelB-Tfu0937-FLAG	-	fragment 7	In-Fusion HD cloning kit
fragment 8	Tfu0937-FLAG_Fw Tfu0937-FLAG_Rv	pHLA-Tfu0937	PCR
pHLA-Tfu0937-FLAG	-	fragment 8	In-Fusion HD cloning kit
fragment 9	phoA_f phoA_r	<i>E. coli</i> MG1655 genomic DNA	PCR
pHLA-phoA	-	fragment 8 fragment 4	In-Fusion HD cloning kit
fragment 10	phoA_S124A_f	pHLA-phoA	PCR

	phoA_S124A_r		
pHLA-phoA ^{S124A}	-	fragment 10	In-Fusion HD cloning kit
fragment 11	pelB_pgi_f1 XhoI_pgi_re	<i>E. coli</i> MG1655 genomic DNA	PCR
pHLA-pelB-pgi	-	fragment 11 fragment 4	In-Fusion HD cloning kit
fragment 12	pgi_H386A_smaI_for pgi_H386A_smaI_re	pHLA-pelB-pgi	PCR
pHLA-pelB-pgi ^{H386A}	-	fragment 12	In-Fusion HD cloning kit
fragment 13	no-sig._pgi_Fw no-sig._pgi_Rv	pHLA-pelB-pgi	PCR
pHLA-pgi	-	fragment 13	In-Fusion HD cloning kit
fragment 14	pelB_zwf_f1 XhoI_zwf_re	<i>E. coli</i> MG1655 genomic DNA	PCR
pHLA-pelB-zwf	-	fragment 14 fragment 4	In-Fusion HD cloning kit
fragment 15	zwf_H239A_pstI_for zwf_H239A_pstI_re	pHLA-pelB-zwf	PCR
pHLA-pelB-zwf ^{H239A}	-	fragment 15	In-Fusion HD cloning kit
fragment 16	no-sig._zwf_Fw no-sig._zwf_Rv	pHLA-pelB-zwf	PCR
pHLA-zwf	-	fragment 16	In-Fusion HD cloning kit
fragment 17	zwf-FLAG_Fw zwf-FLAG_Rv	pHLA-pelB-zwf	PCR
pHLA-pelB-zwf-FLAG	-	fragment 17	In-Fusion HD cloning kit
fragment 18	zwf-FLAG_Fw zwf-FLAG_Rv	pHLA-zwf	PCR
pHLA-zwf-FLAG	-	fragment 18	In-Fusion HD cloning kit
fragment 19	zwf_H239A_pstI_for zwf_H239A_pstI_re	pHLA-pelB-zwf-FLAG	PCR

pHLA-pelB-zwf ^{H239A} -FLAG	-	fragment 19	In-Fusion HD cloning kit
fragment 20	gfp_f1 gfp_r	pEGFP	PCR
fragment 21	gfp_f2 gfp_r	fragment 20	PCR
pHLA-pelB-gfp	-	fragment 21 fragment 4	In-Fusion HD cloning kit
fragment 22	c.n._tfu0937_f c.n._tfu0937_r	pHLA-blc-Tfu0937	PCR
fragment 23	<i>HindIII</i> <i>XhoI</i>	pSAK	Restriction enzyme digestion
pSAK-blc-Tfu0937	-	fragment 22 fragment 23	In-Fusion HD cloning kit
fragment 24	Tfu0937-FLAG_Fw Tfu0937-FLAG_Rv	pSAK-blc-Tfu0937	PCR
pSAK-blc-Tfu0937-FLAG	-	fragment 24	In-Fusion HD cloning kit
fragment 25	<i>HindIII</i> <i>XhoI</i>	pZA23MCS	Restriction enzyme digestion
pZA23-blc-Tfu0937	-	fragment 22 fragment 25	In-Fusion HD cloning kit
fragment 26	Tfu0937-FLAG_Fw Tfu0937-FLAG_Rv	pZA23-blc-Tfu0937	PCR
pZA23-blc-Tfu0937-FLAG	-	fragment 26	In-Fusion HD cloning kit
fragment 27	pZ_EIIB_f pZ_EIIB_r	<i>E. coli</i> MG1655 genomic DNA	PCR
fragment 28	<i>HindIII</i> <i>KpnI</i>	pZA23MCS	Restriction enzyme digestion
pZA23-EIIB ^{Glc}	-	fragment 27 fragment 28	In-Fusion HD cloning kit
fragment 29	pZ_EIIC_f pZ_EIIC_r	<i>E. coli</i> MG1655 genomic DNA	PCR
pZA23-EIIC ^{Glc}	-	fragment 29	

		fragment 28	In-Fusion HD cloning kit
N20 fragment ptsG	sgRNA ptsG Rv sgRNA ptsG Fw	pTargetF	PCR
pTΔptsGF	-	N20 fragment ptsG	In-Fusion HD cloning kit
H.S. fragment ptsG Up	HomSeq Up ptsG Fw HomSeq Up ptsG Rv	<i>E. coli</i> MG1655 genomic DNA	PCR
H.S. fragment ptsG Dw	HomSeq Dw ptsG Fw HomSeq Dw ptsG Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment ptsG	HomSeq Up ptsG Fw HomSeq Dw ptsG Rv	H.S. fragment ptsG Up H.S. fragment ptsG Dw	PCR
pTΔptsGF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔptsGF	Restriction enzyme digestion
pTΔptsG	- -	H.S. fragment ptsG pTΔptsGF fragment	In-Fusion HD cloning kit
N20 fragment crr	sgRNA crr Rv sgRNA crr Fw	pTargetF	PCR
pTΔcrrF	-	N20 fragment crr	In-Fusion HD cloning kit
H.S. fragment crr Up	HomSeq Up crr Fw HomSeq Up crr Rv	<i>E. coli</i> MG1655 genomic DNA	PCR
H.S. fragment crr Dw	HomSeq Dw crr Fw HomSeq Dw crr Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment crr	HomSeq Up crr Fw HomSeq Dw crr Rv	H.S. fragment crr Up H.S. fragment crr Dw	PCR
pTΔcrrF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔcrrF	Restriction enzyme digestion
pTΔcrr	- -	H.S. fragment crr pTΔcrrF fragment	In-Fusion HD cloning kit
N20 fragment pheA	sgRNA pheA Rv sgRNA pheA Fw	pTargetF	PCR

pTΔpheAF	-	N20 fragment pheA	In-Fusion HD cloning kit
H.S. fragment pheA Up	HomSeq Up pheA Fw HomSeq Up pheA Rv	<i>E. coli</i> MG1655 genomic DNA	PCR
H.S. fragment pheA Dw	HomSeq Dw pheA Fw HomSeq Dw pheA Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment pheA	HomSeq Up pheA Fw HomSeq Dw pheA Rv	H.S. fragment pheA Up H.S. fragment pheA Dw	PCR
pTΔpheAF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔpheAF	Restriction enzyme digestion
pTΔpheA	- -	H.S. fragment pheA pTΔpheAF fragment	In-Fusion HD cloning kit
N20 fragment sgrS	sgRNA sgrS Rv sgRNA sgrS Fw	pTargetF	PCR
pTΔsgrSF	-	N20 fragment sgrS	In-Fusion HD cloning kit
H.S. fragment sgrS Up	HomSeq Up sgrS Fw HomSeq Up sgrS Rv	<i>E. coli</i> MG1655 genomic DNA	PCR
H.S. fragment sgrS Dw	HomSeq Dw sgrS Fw HomSeq Dw sgrS Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment sgrS	HomSeq Up sgrS Fw HomSeq Dw sgrS Rv	H.S. fragment sgrS Up H.S. fragment sgrS Dw	PCR
pTΔsgrSF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔsgrSF	Restriction enzyme digestion
pTΔsgrS	- -	H.S. fragment sgrS pTΔsgrSF fragment	In-Fusion HD cloning kit
N20 fragment pgi	sgRNA pgi Rv sgRNA pgi Fw	pTargetF	PCR
pTΔpgiF	-	N20 fragment pgi	In-Fusion HD cloning kit
H.S. fragment pgi Up	HomSeq Up pgi Fw		PCR

	HomSeq Up pgi Rv	<i>E. coli</i> MG1655 genomic DNA	
H.S. fragment pgi Dw	HomSeq Dw pgi Fw HomSeq Dw pgi Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment pgi	HomSeq Up pgi Fw HomSeq Dw pgi Rv	H.S. fragment pgi Up H.S. fragment pgi Dw	PCR
pTΔpgiF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔpgiF	Restriction enzyme digestion
pTΔpgi	- -	H.S. fragment pgi pTΔpgiF fragment	In-Fusion HD cloning kit
N20 fragment trpE	sgRNA trpE Rv sgRNA trpE Fw	pTargetF	PCR
pTΔtrpEF	-	N20 fragment trpE	In-Fusion HD cloning kit
H.S. fragment trpE Up	HomSeq Up trpE Fw HomSeq Up trpE Rv	<i>E. coli</i> MG1655 genomic DNA	PCR
H.S. fragment trpE Dw	HomSeq Dw trpE Fw HomSeq Dw trpE Rv	<i>E. coli</i> MG1656 genomic DNA	PCR
H.S. fragment trpE	HomSeq Up trpE Fw HomSeq Dw trpE Rv	H.S. fragment trpE Up H.S. fragment trpE Dw	PCR
pTΔtrpEF fragment	<i>HindIII</i> <i>EcoRI</i>	pTΔtrpEF	Restriction enzyme digestion
pTΔtrpE	- -	H.S. fragment trpE pTΔtrpEF fragment	In-Fusion HD cloning kit
fragment 30	tyr_ins Fw tyr_ins Rv	pSAK- <i>tyrA</i> ^{fbr}	PCR
fragment 31	<i>SpeI</i>	pTΔtrpE	Restriction enzyme digestion
pTtrpE::tyrfbr	-	fragment 30 fragment 31	In-Fusion HD cloning kit
fragment 32	pTptsG_inv.Fw pTptsG_inv.Rv	pTΔptsG	PCR
fragment 32	galP-gluk_ins Fw		PCR

	galP-gl _k _ins R _v	CFT1 genomic DNA	
pTptsG::galP-gl _k	-	fragment 32	In-Fusion HD
		fragment 33	cloning kit

SI References

- Fujiwara, R., Noda, S., Tanaka, T., Kondo, A., 2020. Metabolic engineering of *Escherichia coli* for shikimate pathway derivative production from glucose–xylose co-substrate. Nat. Commun. 11, 1–12. <https://doi.org/10.1038/s41467-019-14024-1>
- Noda, S., Shirai, T., Mori, Y., Oyama, S., Kondo, A., 2017. Engineering a synthetic pathway for maleate in *Escherichia coli*. Nat. Commun. 8, 1153. <https://doi.org/10.1038/s41467-017-01233-9>
- Noda, S., Shirai, T., Oyama, S., Kondo, A., 2016. Metabolic design of a platform *Escherichia coli* strain producing various chorismate derivatives. Metab. Eng. 33, 119–129. <https://doi.org/10.1016/j.ymben.2015.11.007>
- Tanaka, T., Kawabata, H., Ogino, C., Kondo, A., 2011. Creation of a cellobiosaccharide-assimilating *Escherichia coli* strain by displaying active beta-glucosidase on the cell surface via a novel anchor protein. Appl. Environ. Microbiol. 77, 6265–70. <https://doi.org/10.1128/AEM.00459-11>